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Introduction	  The	  pharmaceutical	  industry	  urgently	  needs	  new	  ways	  of	  profiling	  the	  safety	  and	  efficacy	  of	  new	  cardiovascular	  (CV)	  drugs	  and	  more	  effectively	  transitioning	  these	  compounds	  through	  the	  stages	  of	  CV	  drug	  screening.	  In	  this	  article	  we	  review	  new	  technologies	  and	  methodological	  innovations	  and	  assess	  whether	  these	  frameworks	  offer	  improved	  solutions	  to	  the	  problems	  facing	  the	  contemporary	  CV	  drug	  development.	  	  	  
Areas	  covered	  We	  performed	  a	  systematic	  search	  of	  the	  patent	  literature	  (from	  2000	  onwards)	  using	  US	  Patent	  Office	  and	  ESP@CENET	  search	  engines	  and	  multiple	  Boolean	  terms.	  We	  focussed	  on	  patents	  relating	  to	  technologies	  and	  resources	  and	  categorised	  the	  patents	  according	  to	  their	  niche	  in	  the	  CV	  drug	  screening	  landscape	  (molecular,	  cellular,	  organ	  and	  model	  organism,	  bioinformatics	  systems).	  	  
	  
Expert	  Opinion	  The	  CV	  drug	  pipeline	  is	  stalling	  due	  to	  the	  inability	  of	  many	  contemporary	  drug	  screening	  frameworks	  to	  robustly	  discriminate	  between	  safe,	  efficacious	  therapy	  and	  hazardous	  off-­‐target	  effect.	  Given	  the	  current	  limitations	  of	  drug	  screening	  frameworks,	  there	  is	  little	  scope	  for	  expanding	  the	  CV	  drug	  portfolio	  with	  newer,	  safer	  drugs	  with	  improved	  mechanisms	  of	  action.	  New	  drug	  screening	  modalities	  are	  urgently	  needed.	  Our	  searches	  reveal	  that	  there	  are	  few	  examples	  of	  truly	  new	  technologies	  and	  systems	  in	  the	  patent	  literature.	  This	  apparent	  failure	  to	  fundamentally	  revamp	  facets	  of	  the	  CV	  drug	  screening	  process	  may	  serve	  only	  to	  perpetuate	  the	  inability	  of	  current	  platforms	  to	  improve	  the	  CV	  drug	  pipeline.	  Consequently,	  with	  some	  exceptions	  such	  as	  stem-­‐cell	  derived	  cardiomyocytes,	  cell	  engineering	  and	  the	  emergence	  of	  phenotypic	  screening,	  there	  is	  stagnation	  in	  pre-­‐clinical	  assay	  design	  that	  limits	  the	  pharmaceutical	  industry’s	  ability	  to	  search	  for	  new	  drugs	  in	  new	  and	  more	  effective	  ways.	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• There	  is	  an	  unacceptably	  high	  attrition	  of	  CV	  drugs	  in	  safety	  assessments	  that	  stems	  from	  the	  failure	  of	  existing	  screening	  frameworks	  to	  appropriately	  assess	  the	  hazards	  (and	  as	  a	  corollary,	  identify	  beneficial	  off	  target	  effects)	  of	  new	  compounds.	  
• The	  pharmaceutical	  industry	  desperately	  needs	  new	  ways	  of	  screening	  drugs	  and	  better	  transitioning	  of	  lead	  compounds	  through	  the	  drug	  development	  process.	  
• In	  the	  article,	  we	  review	  recent	  patents	  in	  technologies	  and	  methods	  development	  in	  CV	  drug	  screening,	  covering	  the	  stages	  of	  molecules	  to	  cells,	  cells	  to	  syncytia,	  syncytia	  to	  organs	  and	  model	  systems,	  and	  model	  systems	  to	  the	  human	  scenario.	  
• Aside	  from	  the	  phenomenal	  progress	  in	  stem-­‐cell	  technologies,	  tissue	  engineering	  and	  the	  emergence	  of	  phenotypic	  screens,	  we	  found	  few	  examples	  of	  truly	  innovation	  in	  the	  CV	  drug	  screening	  patent	  literature.	  
• We	  argue	  that	  by	  employing	  strategies	  that	  are	  essentially	  refinements	  of	  decades-­‐old	  technologies,	  the	  same	  types	  of	  candidate	  molecules	  will	  be	  unearthed	  that	  exhibit	  the	  same	  hazard-­‐to-­‐benefit	  profiles	  as	  existing	  pharmacologies.	  
• We	  anticipate	  that	  the	  paucity	  of	  new	  modalities	  for	  improved	  safety	  and	  efficacy	  profiling	  will	  perpetuate	  the	  inability	  of	  the	  CV	  drug	  development	  process	  to	  fully	  assess	  the	  torrent	  of	  new	  candidate	  molecules	  that	  are	  emerging	  from	  high-­‐throughput,	  automated	  lead	  compound	  discovery.	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1.	  Introduction	  In	  2008,	  we	  focussed	  on	  the	  status	  of	  cardiovascular	  (CV)	  drug	  discovery	  and	  development	  in	  industrial	  and	  academic	  environments	  1.	  Although	  there	  is	  a	  general	  downward	  trend	  in	  the	  approval	  of	  new	  medical	  entities	  (NMEs)	  2	  that	  contrasts	  sharply	  with	  the	  huge	  pharmaceutical	  industry	  investment	  in	  R&D,	  this	  situation	  is	  critical	  in	  the	  CV	  sphere	  where	  remarkably	  few	  new	  cardiac	  drugs	  are	  emerging	  from	  the	  development	  pipeline.	  New	  drugs	  with	  innovative	  and	  plausible	  mechanisms	  of	  action	  are	  being	  brought	  through	  the	  system	  1,	  3-­‐6	  but	  in	  disappointingly	  small	  numbers	  that	  are	  disproportionate	  to	  the	  enormous	  disease	  burden	  of	  CV	  disease.	  In	  the	  wake	  of	  the	  high-­‐profile	  problems	  associated	  with	  COX-­‐2	  inhibitors	  (rofecoxib	  (Vioxx®,	  Merck),	  valdecoxib	  (Bextra®,	  Searle	  &	  Company),	  celecoxib	  (Celebrex®,	  Pfizer))	  7,	  8	  and	  more	  recently	  the	  PPARγ	  ligands	  (e.g.	  rosiglitazone	  (Avandia®,	  GSK))	  9,	  10,	  the	  pharmaceutical	  sector	  was	  sensitised	  to	  ‘safety	  versus	  efficacy’	  issues.	  With	  a	  few	  exceptions,	  industry	  appeared	  to	  be	  re-­‐purposing	  and	  refining	  pre-­‐existing	  concepts	  rather	  than	  focussing	  on	  ab	  initio	  drug	  development	  since	  this	  strategy	  negates	  the	  exorbitant	  cost	  and	  chronicity	  of	  bringing	  drugs	  to	  market	  (presently	  estimated	  to	  cost	  in	  excess	  of	  $800million	  and	  take	  an	  average	  of	  15	  years	  for	  a	  single	  drug)11.	  The	  reversion	  to	  re-­‐positioning	  apparently	  safe	  drugs	  with	  demonstrated	  efficacy	  in	  other	  therapeutic	  settings	  into	  the	  CV	  arena	  was	  contrasted	  by	  the	  remarkably	  innovative	  and	  novel	  solutions	  offered	  by	  the	  academic	  and	  smaller	  enterprises	  sector	  1.	  This	  paradox	  between	  innovative	  drug	  discovery	  and	  the	  anaemic	  CV	  drug	  pipeline,	  although	  clearly	  impacted	  by	  prohibitive	  cost	  and	  time	  issues,	  may	  point	  towards	  the	  pharmaceutical	  industry’s	  inability	  to	  select	  and	  steer	  better	  and	  safer	  compounds,	  in	  sufficient	  number,	  through	  the	  labyrinthine	  world	  of	  drug	  screening.	  Consequently,	  the	  unacceptably	  high	  attrition	  of	  CV	  drugs	  in	  pre-­‐clinical	  safety	  assessments	  is	  due	  in	  part	  to	  the	  failure	  of	  existing	  screening	  frameworks	  to	  appropriately	  assess	  the	  hazards	  (and	  as	  a	  corollary,	  identify	  serendipidous	  off-­‐target	  benefits)	  of	  new	  compounds.	  Our	  conclusion	  was	  that	  the	  pharmaceutical	  industry	  desperately	  needed	  new	  ways	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of	  screening	  drugs	  and	  more	  effectively	  transitioning	  these	  compounds	  through	  the	  stages	  of	  the	  drug	  development	  pipeline.	  In	  this	  article	  we	  provide	  an	  objective	  review	  of	  developments	  in	  drug	  screening	  modalities	  covering	  genetic,	  molecular,	  cellular	  and	  animal	  model	  systems.	  We	  assess	  whether	  these	  advances	  offer	  improved	  solutions	  to	  the	  problems	  facing	  the	  contemporary	  CV	  drug	  development.	  	  
	  
2.	  Review	  criteria	  Previously,	  we	  reviewed	  patent	  documents	  that	  specifically	  described	  the	  development	  of	  new	  CV	  pharmacologies	  1.	  We	  included	  filings	  of	  interest	  that	  spanned	  the	  range	  from	  Patent	  Co-­‐operation	  Treaty	  filings	  (PCT)	  through	  to	  granted	  patents	  and	  we	  took	  this	  wide-­‐ranging	  approach	  in	  order	  to	  assess	  the	  levels	  of	  grass	  roots	  innovation	  in	  CV	  pharmacology.	  Indeed,	  at	  the	  time	  of	  writing	  only	  3	  were	  full	  patents.	  In	  the	  intervening	  three-­‐plus	  years	  since	  2008,	  from	  our	  coverage	  of	  45	  patent	  filings	  that	  were	  at	  application	  stage	  (PCT	  to	  ‘A’	  status),	  11	  have	  now	  been	  granted	  full	  status	  (24%)	  and	  13	  (29%)	  are	  still	  under	  consideration.	  However,	  15	  filings	  (33%)	  have	  since	  been	  withdrawn.	  Although	  there	  are	  multiple	  reasons	  for	  this	  ‘drop-­‐out’,	  including	  the	  high	  costs	  of	  remaining	  in	  the	  system,	  it	  affirms	  our	  belief	  that	  innovation	  is	  not	  being	  efficiently	  transposed	  to	  market	  development.	  The	  unpredictable	  nature	  of	  the	  outcome	  of	  many	  patent	  applications	  prompted	  us	  to	  confine	  our	  search	  in	  the	  present	  article	  to	  only	  those	  that	  had	  been	  granted	  full	  patent	  status	  (i.e.	  ‘B’).	  	  	  Patents	  and	  their	  archival	  databases	  are	  notoriously	  opaque;	  keywords	  and	  search	  terms	  are	  frequently	  secreted	  away	  in	  obscure	  portions	  of	  the	  text	  and	  thus	  comprehensive	  searching	  of	  the	  patent	  literature	  is	  difficult.	  Some	  documents	  are	  wilfully	  vague	  presumably	  in	  order	  to	  avoid	  detailed	  searches.	  To	  tackle	  this	  issue,	  we	  performed	  a	  systematic	  search	  of	  the	  patent	  literature	  (from	  2000	  onwards)	  through	  the	  US	  patent	  office	  12	  and	  ESP@CENET	  (that	  indexes	  both	  European	  and	  US	  patents)	  13	  search	  engines	  using	  multiple	  Boolean	  terms	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defined	  in	  Table	  1.	  Search	  hits	  were	  refined	  according	  to	  the	  scheme	  described	  in	  Figure	  1,	  and	  we	  excluded	  any	  document	  that	  related	  specifically	  to	  natural	  and	  synthetic	  pharmacologies,	  medicinal	  agents	  and	  hardware	  (medical	  devices)	  since	  these	  fell	  outside	  of	  the	  present	  remit	  to	  evaluate	  screening	  technologies	  and	  tools.	  We	  also	  excluded	  any	  documents	  relating	  to	  DNA	  sequences	  of	  mutant	  ion	  channels,	  since	  with	  some	  rare	  exceptions	  (e.g.	  a	  novel	  tension	  dependent	  channel	  14),	  patents	  in	  this	  area	  are	  primarily	  adding	  to	  the	  catalogue	  of	  disease-­‐linked	  mutations	  in	  already	  reported	  genetic	  loci.	  We	  did	  however	  consider	  patents	  relating	  to	  newly-­‐identified	  common	  DNA	  variants	  (polymorphisms)	  associated	  with	  arrhythmias	  since	  this	  is	  a	  field	  of	  burgeoning	  interest	  15,	  16.	  	  Table	  1	  shows	  that	  our	  two	  complementary	  search	  modes	  (full-­‐text	  searching	  (US	  Patents)	  and	  abstract	  and	  title-­‐type	  searching	  (ESP@CENET))	  yielded	  comparable	  coverage	  of	  the	  search	  terms.	  We	  classified	  the	  selected	  patents	  into	  model	  organisms,	  cell	  systems,	  sequencing	  and	  bioinformatics	  and	  screening	  technologies	  (Figure	  1)	  and	  used	  these	  as	  the	  basis	  to	  structure	  the	  present	  article.	  	  
3.	  The	  need	  to	  redefine	  screening	  technologies	  The	  pharmaceutical	  industry	  utilises	  an	  array	  of	  pre-­‐clinical	  screening	  approaches	  to	  profile	  CV	  drug	  safety	  and	  efficacy.	  These	  include	  sophisticated	  technological	  platforms	  such	  as	  automated	  patch	  clamping,	  microelectrode	  arrays	  (MEAs)	  and	  advanced	  microscopy	  for	  enhanced	  cellular	  imaging.	  These	  approaches	  are	  complemented	  by	  lower	  throughput	  ‘conventional’	  in	  vitro	  testing	  that	  include	  Purkinje	  fibre-­‐based	  action	  potential	  duration	  (APD)	  assays,	  canine	  wedge	  preparations	  and	  Langendorff	  perfused	  rabbit	  hearts	  and	  evaluation	  using	  in	  vivo	  models	  of	  arrhythmia	  (animal	  models	  of	  chronic	  atrio-­‐ventricular	  block,	  failing	  rabbit	  hearts,	  paced	  canine	  hearts).	  These	  and	  other	  contemporary	  drug	  screening	  modalities	  have	  been	  recently	  reviewed	  17-­‐19	  (see	  also	  Table	  2).	  The	  combined	  outputs	  from	  these	  systems	  are	  used	  to	  provide	  an	  integrated	  assessment	  of	  drug	  safety	  and	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efficacy	  in	  line	  with	  current	  European	  and	  US	  regulatory	  mandates	  20,	  21.	  Notably,	  the	  shortcomings	  of	  these	  outdated	  guidelines	  have	  been	  exposed.	  For	  example,	  they	  do	  not	  cover	  the	  potential	  of	  drugs	  to	  shorten	  the	  QT	  interval	  that	  may	  exacerbate	  arrhythmias	  and	  it	  has	  been	  argued	  that	  these	  criteria	  need	  to	  be	  overhauled	  22,	  23.	  We	  consider	  this	  issue	  further	  in	  Section	  4	  (From	  molecules	  to	  cells).	  The	  early	  stages	  of	  CV	  drug	  screening	  involve	  molecular	  and	  cellular	  profiling	  of	  lead	  compounds	  and	  here	  there	  is	  a	  pervasive	  drive	  towards	  automation,	  miniaturisation,	  and	  nanotechnologies	  that	  enable	  ever-­‐higher	  throughputs	  to	  be	  achieved.	  Impressive	  as	  these	  technological	  achievements	  are,	  many	  of	  these	  new	  platforms	  are	  prone	  to	  the	  same	  problems	  that	  plague	  their	  lower-­‐throughput	  configurations	  (e.g.	  cell	  quality,	  fragility	  of	  membranes	  in	  automated	  patch	  clamping	  24).	  Moreover,	  from	  an	  industrial	  perspective	  it	  has	  been	  suggested	  that	  too	  many	  of	  these	  assay	  types	  are	  prone	  to	  artefact	  and	  bias	  19.	  Importantly,	  there	  is	  a	  fundamental	  issue	  that	  directly	  impacts	  on	  the	  ability	  to	  search	  for	  new	  drugs	  in	  new	  ways	  -­‐	  the	  basis	  of	  these	  assays	  has	  remained	  unchanged	  for	  decades.	  The	  perception	  of	  methodological	  stagnation,	  at	  least	  in	  terms	  of	  the	  paucity	  of	  patents	  relating	  to	  truly	  new	  platform	  modalities	  for	  CV	  drug	  screening	  is	  corroborated	  by	  our	  searches	  that	  revealed	  that	  half	  of	  the	  new	  patents	  describing	  screening	  technologies	  (Figure	  1)	  are	  essentially	  glorified	  electrophysiological	  platforms	  25-­‐29.	  One	  patent	  describes	  an	  antibody-­‐based	  method	  for	  profiling	  cell-­‐surface	  expression	  of	  cardiac	  ion	  channels	  or	  for	  investigating	  the	  total	  amount	  of	  protein	  within	  a	  cell	  30.	  Another	  claims	  that	  an	  assessment	  of	  differential	  gene	  expression	  profiles	  evoked	  by	  drug-­‐treatment	  could	  be	  used	  in	  predicting	  pharmacotoxicity	  within	  cell	  populations	  31.	  However,	  both	  of	  these	  examples	  involve	  the	  adaptation	  of	  rather	  conventional	  techniques	  into	  the	  CV	  drug-­‐screening	  arena	  and	  do	  not	  typify	  genuinely	  innovative	  solutions.	  The	  majority	  of	  cell-­‐based	  screens	  are	  designed	  to	  investigate	  short-­‐term	  phenotypic	  and	  molecular	  changes.	  But	  where	  are	  those	  systems	  for	  interrogating	  more	  ‘slow-­‐burning’	  phenotypic	  changes?	  Subtle	  drug-­‐induced	  changes	  in	  cardiac	  cell	  ion	  handling	  and	  signalling	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may	  eventually	  lead	  to	  necrosis,	  apoptosis	  and	  autophagy	  over	  the	  course	  of	  many	  days	  or	  weeks	  -­‐	  timescales	  that	  are	  incompatible	  with	  high	  content	  screening	  (HCS)	  assays.	  Likewise,	  the	  ability	  of	  small	  molecules	  or	  biologics	  to	  correct	  the	  chronic	  intracellular	  trafficking	  defects	  associated	  with	  many	  mutations	  in	  the	  human	  ether-­‐a-­‐go-­‐go	  channel	  gene	  (hERG)	  (channelopathic	  mutants	  that	  underpin	  long	  QT	  syndrome	  (LQTS)	  type	  2)	  is	  unlikely	  to	  be	  robustly	  examined	  by	  current	  HCS	  platforms.	  Thus,	  systems	  for	  interrogating	  longer-­‐term	  effects	  of	  drug	  exposure	  (e.g.	  latent	  toxicity)	  and	  other	  more	  gradual	  phenotypic	  changes	  have	  yet	  to	  be	  properly	  configured.	  So,	  the	  persistently	  high	  attrition	  of	  CV	  drugs	  in	  the	  development	  pipeline	  directly	  suggests	  that	  contemporary	  drug	  screening	  frameworks	  are	  not	  sufficiently	  discriminatory	  to	  drive	  the	  discovery	  of	  newer,	  safer	  drugs	  with	  improved	  mechanisms	  of	  action.	  We	  argue	  that	  by	  employing	  strategies	  that	  are	  essentially	  refinements	  of	  decades-­‐old	  technologies,	  the	  same	  types	  of	  candidate	  molecules	  will	  be	  unearthed	  that	  exhibit	  the	  same	  hazard-­‐to-­‐benefit	  profiles	  and	  the	  development	  pipeline	  will	  stagnate.	  Innovative	  screening	  platforms	  are	  urgently	  required.	  	  
4.	  From	  molecules	  to	  cells:	  moving	  towards	  phenotypic	  screening	  strategies	  As	  was	  noted	  over	  a	  decade	  ago,	  “molecularly	  orientated	  studies	  dealing	  with	  transcript	  determinations,	  gene	  actions	  and	  interactions,	  protein-­‐protein	  interactions	  and	  signal	  transduction	  pathways,	  although	  obviously	  valuable	  in	  their	  own	  rights,	  fail	  to	  define	  over	  the	  lifetimes	  of	  the	  animals	  the	  changes	  that	  occur	  at	  the	  whole	  organ	  and	  whole	  animal	  levels”	  32.	  While	  molecule-­‐centric	  approaches	  are	  valid	  in	  diseases	  with	  established	  culprits,	  in	  complex	  disorders	  such	  as	  CV	  disease	  that	  may	  be	  characterised	  by	  the	  collectivised	  abnormalities	  of	  ion	  channels,	  regulatory	  proteins	  and	  genetic	  and	  epigenetic	  factors,	  it	  is	  very	  difficult	  to	  identify	  drugable	  targets.	  Even	  in	  those	  instances	  in	  which	  cardiac	  disease	  may	  be	  attributable	  to	  discrete	  molecular	  dysfunction	  (e.g.	  monogenic	  ion	  channeopathies)	  there	  are	  problems	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associated	  with	  this	  approach.	  For	  example,	  determining	  the	  liability	  of	  a	  drug	  to	  block	  hERG,	  the	  channel	  that	  mediates	  important	  repolarization	  current	  in	  humans	  (IKr)	  is	  a	  mandatory	  requirement	  of	  FDA	  and	  EMA	  guidelines	  20,	  21.	  However,	  specifically	  configuring	  a	  molecular	  screen	  to	  identify	  lead	  compounds	  that	  do	  not	  block	  hERG	  is	  of	  limited	  value	  in	  defining	  their	  likely	  hazards	  in	  a	  clinical	  setting	  because	  human	  arrhythmicity	  is	  governed	  by	  currents	  other	  than	  those	  carried	  by	  hERG	  33.	  Furthermore,	  the	  relationship	  between	  hERG	  blockade	  and	  arrhythmia	  is	  complex	  since	  many	  drugs	  that	  block	  hERG	  do	  not	  cause	  arrhythmias	  (e.g.	  verapamil,	  amiodarone)	  while	  some	  agents	  that	  do	  not	  directly	  block	  hERG	  are	  potent	  arrhythmogens	  (e.g.	  arsenic	  trioxide)	  33-­‐35.	  Thus,	  such	  a	  molecular-­‐centric	  assay	  may	  conspicuously	  fail	  to	  identify	  the	  hazardous	  or	  beneficial	  off-­‐target	  effects	  of	  the	  drug	  under	  test.	  The	  impact	  of	  such	  issues	  in	  the	  CV	  drug	  pipeline	  is	  substantial;	  it	  is	  estimated	  that	  40-­‐70%	  of	  new	  chemical	  entities	  are	  abandoned	  because	  of	  hERG	  liability	  leading	  to	  calls	  that	  many	  of	  these	  ‘failures’	  should	  be	  re-­‐evaluated	  in	  improved	  assays	  34,	  36.	  So,	  considering	  the	  limitations	  of	  some	  molecularly-­‐centric	  assays,	  for	  example	  HERG	  liability	  which	  is	  considered	  by	  some	  to	  be	  a	  poor	  surrogate	  for	  arrhythmogenic	  liability	  in	  
vivo	  37,	  there	  is	  value	  in	  moving	  towards	  phenotype-­‐based	  screening	  modes	  that	  identify	  lead	  compounds	  that,	  as	  Peal	  and	  colleagues	  eloquently	  phrased,	  “modify	  the	  disease	  trait	  in	  a	  mechanistically	  agnostic	  fashion”	  38.	  This	  is	  allied	  to	  the	  concept	  of	  ‘magic	  shotguns’	  (not	  bullets!)	  through	  which	  improved	  clinical	  efficacy	  is	  driven	  by	  pleiotropic	  agents	  that	  act	  on	  multiple	  cellular	  targets	  39.	  The	  utility	  of	  model	  organisms	  for	  phenotypic	  screening	  of	  CV	  drugs	  is	  discussed	  in	  Section	  8	  (From	  organs	  to	  model	  organisms).	  	  
5.	  From	  molecules	  to	  cells	  -­	  the	  stem-­cell	  revolution	  The	  heterologous	  expression	  of	  recombinant	  proteins	  in	  mammalian	  cells	  (e.g.	  CHO,	  HEK,	  HeLa)	  is	  a	  powerful	  tool	  for	  the	  dissection	  of	  molecular	  function.	  Whilst	  these	  systems	  provide	  a	  more	  native	  background	  for	  the	  study	  of	  ion	  channels	  than	  non-­‐mammalian	  ones	  (e.g.	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Xenopus)	  not	  least	  in	  their	  dose-­‐response	  profile	  to	  drug	  dosing	  24,	  they	  fail	  to	  recreate	  the	  hallmark	  functional,	  contractile	  and	  electrical	  properties	  of	  cardiac	  cells.	  Ultimately	  these	  non-­‐cardiac	  ‘industrial’	  cell	  types	  bear	  little	  physiological	  relevance	  to	  the	  environment	  in	  which	  the	  drugs	  will	  ultimately	  be	  expected	  to	  work.	  Their	  use	  is	  prone	  to	  false	  positives	  (safe	  drugs	  that	  appear	  hazardous)	  and	  the	  more	  common	  false	  negatives	  (hazardous	  drugs	  that	  have	  no	  overt	  dysfunctional	  properties).	  	  A	  solution	  to	  some	  of	  these	  issues	  is	  presented	  by	  the	  method	  of	  generating	  beating	  heart	  cell	  clusters	  from	  neonatal	  hearts	  that	  can	  be	  used	  for	  investigating	  the	  effects	  of	  drugs	  on	  heart	  rate	  and	  rhythm	  (i.e.	  a	  phenotype	  screen)	  40.	  This	  technology	  enables	  the	  use	  of	  virally-­‐transduced	  animal	  cells	  to	  reproduce	  sinus	  node	  cardiac	  pacemaker	  function	  that	  may	  be	  combined	  with	  voltage-­‐	  and	  Ca2+-­‐sensitive	  dyes	  to	  monitor	  cellular	  beat	  rate.	  Clearly,	  a	  screening	  strategy	  based	  on	  human	  cardiac	  cells	  obviates	  the	  species-­‐specific	  problems	  that	  plague	  the	  use	  of	  cells	  derived	  from	  mouse,	  rat,	  rabbit	  and	  dog.	  The	  phenomenal	  conceptual	  and	  technical	  progress	  that	  has	  been	  accomplished	  in	  human	  pluripotent	  stem	  cells	  (hPSC,	  a	  term	  that	  encompasses	  both	  embryonic	  stem	  cells	  (ES)	  and	  induced	  pluripotent	  stem	  cells	  (iPS))	  has	  seen	  their	  emergence	  as	  genuinely	  new	  cell	  platforms	  for	  CV	  drug	  screening.	  The	  stunning	  technical	  feat	  of	  reprogramming	  mouse	  fibroblasts	  to	  iPS	  cells	  using	  virally-­‐driven	  expression	  of	  four	  cardiopoetic	  factors	  (Oct4,	  Sox2,	  Klf4	  and	  c-­‐Myc)	  41	  was	  soon	  followed	  by	  the	  generation	  of	  iPS	  cells	  from	  adult	  human	  fibroblasts	  using	  the	  same	  factors	  42	  or	  a	  modified	  protocol	  (Oct4,	  Sox2,	  Nanog	  and	  LIN28)	  43	  and	  also	  from	  foetal	  and	  neonatal	  fibroblasts	  44.	  An	  important	  development	  came	  from	  Zhang	  and	  colleagues	  who	  reported	  a	  methodology	  for	  obtaining	  functionally	  competent	  cardiomyocytes	  from	  human	  iPS	  cells	  45,	  although	  it	  is	  acknowledged	  that	  efficient	  and	  reproducible	  differentiation	  into	  cardiomyocytes	  remains	  a	  challenge.	  In	  our	  searches,	  we	  did	  not	  find	  any	  patents	  relating	  specifically	  to	  ES-­‐derived	  cardiomyocytes	  since	  there	  is	  a	  legal	  preclusion	  to	  the	  granting	  of	  a	  patent	  to	  any	  material	  that	  has	  involved	  the	  destruction	  of	  an	  
EOTP_2011_0055R1 
 11 
embryo	  46.	  Notably,	  patenting	  in	  the	  iPS	  cell	  field,	  although	  not	  prevented	  by	  the	  same	  legislation	  that	  governs	  ES	  cells,	  is	  mired	  in	  controversy	  over	  priority	  due	  in	  part	  to	  the	  US	  system	  of	  “first	  to	  invent”	  versus	  the	  European	  and	  Japanese	  schemes	  of	  “first	  to	  file”	  47-­‐49.	  Despite	  feverish	  levels	  of	  activity	  in	  patent	  applications	  relating	  to	  iPS	  technologies,	  we	  were	  surprised	  that	  so	  few	  patents	  relating	  specifically	  to	  iPS	  cells	  had	  been	  granted	  50-­‐52.	  To	  illustrate	  this,	  Shinya	  Yamanaka,	  whose	  group	  first	  generated	  iPS	  cells	  41	  has	  filed	  twenty-­‐eight	  patent	  applications	  relating	  to	  methods	  development	  in	  iPS	  cellular	  technologies,	  that	  includes	  the	  one	  granted	  in	  Japan	  50.	  However,	  at	  the	  time	  of	  preparing	  this	  article,	  none	  of	  them	  had	  been	  granted	  full	  patent	  status	  in	  the	  US.	  To	  date,	  almost	  all	  of	  the	  patents	  granted	  in	  the	  ES-­‐	  and	  iPS	  sphere	  relate	  primarily	  to	  methodological	  and	  protocol	  development	  that	  optimise	  the	  processes	  rather	  than	  patenting	  the	  cellular	  entity	  53-­‐56.	  Thus	  at	  present	  many	  commercial	  organisations	  have	  full	  freedom	  to	  operate	  in	  this	  arena.	  Given	  the	  breathtaking	  pace	  of	  progress	  in	  this	  field,	  it	  is	  entirely	  likely	  that	  some	  technologies	  under	  consideration	  will	  be	  obsolete	  before	  the	  patent	  is	  prosecuted	  49	  and	  we	  believe	  that	  the	  present	  legal	  complexities	  will	  remain	  for	  some	  time	  to	  come.	  Subsequent	  refinements	  to	  reprogramming	  methodologies	  have	  improved	  the	  biosafety	  and	  downstream	  applicability	  of	  iPS	  cells	  57,	  58	  and	  these	  are	  fuelling	  the	  anticipated	  utility	  of	  these	  cell	  types	  in	  cardiac	  regeneration	  strategies	  via	  autologous	  transplantation	  59-­‐
61.	  However,	  this	  therapeutic	  goal	  may	  be	  significantly	  delayed	  due	  to	  complications	  associated	  with	  hPSC	  cell	  types.	  The	  pluripotency	  of	  ES-­‐derived	  cells	  leads	  to	  teratoma	  formation	  upon	  implantation	  and	  this	  limits	  their	  usefulness	  in	  this	  context.	  Elsewhere,	  iPS	  cells	  exhibit	  by	  aberrant	  epigenetic	  phenomena	  (DNA	  methylation,	  histone	  acetylation)	  and	  an	  increased	  frequency	  of	  somatic	  coding	  mutations	  that	  persist	  in	  the	  post-­‐differentiation	  state	  62-­‐65.	  	  Given	  these	  present	  preclusions,	  the	  most	  immediate	  natural	  fit	  for	  these	  amazing	  cellular	  resources	  in	  the	  drug	  landscape	  is	  in	  screening	  programmes	  66-­‐68.	  Indeed,	  iPS-­‐derived	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cardiomyocytes	  have	  already	  been	  used	  for	  this	  purpose	  and	  it	  appears	  that	  pharmacobehaviour	  in	  iPS-­‐derived	  cardiomyocytes	  is	  similar	  to	  that	  observed	  with	  human	  ES-­‐derived	  cardiac	  cells	  45,	  69.	  Consequently,	  huge	  investment	  is	  being	  poured	  into	  the	  industrial	  generation	  of	  ES-­‐	  and	  iPS-­‐derived	  cardiomyocytes.	  The	  commercial	  availability	  of	  hPSC-­‐derived	  cardiac	  cells	  (e.g.	  GE	  Healthcare’s	  Cytiva	  (ES-­‐derived)	  and	  CDI’s	  iCell	  (iPS-­‐derived))	  obviates	  the	  practical	  challenges	  in	  reproducibly	  deriving	  phenotypically	  competent	  cardiomyocytes	  from	  ES	  and	  iPS	  cells.	  Moreover,	  augmenting	  these	  cellular	  resources	  with	  approaches	  that	  incorporate	  genetic	  selection	  using	  transgenes	  encoding	  fluorescent	  reporters	  or	  antibiotic	  selectable	  resistance	  enables	  the	  expansion	  to	  bioreactor	  scale	  culture	  compatible	  with	  HTS.	  However,	  the	  phenotypic	  reproducibility	  of	  the	  cells	  through	  the	  manufacturing	  process	  is	  crucial.	  Not	  all	  the	  cells	  derived	  from	  hPSC	  protocols	  are	  functional	  cardiomyocytes	  (although	  methods	  have	  been	  described	  to	  improve	  the	  overall	  yield	  of	  cardiomyocytes	  55,	  70)	  and	  fibroblast	  ‘contamination’	  is	  persistent	  and	  extremely	  variable.	  Also,	  even	  cardiomyocytes	  derived	  from	  ES-­‐	  and	  iPS	  cells	  are	  phenotypically	  heterogeneous	  remaining	  embryonic-­‐like	  in	  terms	  of	  size,	  organisation	  and	  electrical	  properties	  and	  proteomic	  profile	  even	  after	  functional	  maturation	  via	  prolonged	  culture	  (>50	  days)	  45,	  60,	  71.	  Consequently,	  the	  validity	  of	  using	  hPSC-­‐derived	  cells	  as	  bona	  fide	  adult	  ventricular	  and	  atrial	  cells	  is	  open	  to	  question.	  Similarly,	  the	  drive	  towards	  phenotypic	  enrichment	  of	  a	  ‘pure’	  cardiomyocyte	  population	  moves	  further	  away	  from	  the	  multi-­‐cellular	  mosaicism	  that	  characterises	  the	  myocardium	  in	  vivo.	  	   The	  ability	  to	  generate	  iPS-­‐derived	  cardiomyocytes	  from	  patients	  affected	  by	  monogenic	  arrhythmia	  disorders	  (including	  LQT1	  72,	  LQT2	  73,	  74	  and	  Timothy	  syndrome	  75)	  potentially	  leads	  to	  a	  new	  era	  of	  drug	  toxicological	  and	  efficacy	  profiling.	  iPS-­‐derived	  cardiomyocytes	  from	  these	  individuals	  appear	  to	  recapitulate	  the	  molecular	  and	  cellular	  dysfunction	  associated	  with	  the	  human	  disease.	  For	  example,	  LQTS-­‐patient	  derived	  cardiac	  cells	  exhibit	  electrophysiological	  and	  gene-­‐expression	  dysfunction	  in	  ventricular,	  atrial	  and	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nodal	  cell	  populations	  72	  whereas	  in	  iPS-­‐derived	  cardiomyocytes	  from	  a	  patient	  with	  Timothy	  syndrome,	  the	  disease-­‐linked	  abnormalities	  are	  restricted	  to	  a	  ventricular-­‐like	  cell	  population	  
75.	  These	  data	  point	  to	  the	  disease-­‐specific	  functional	  segregation	  of	  cardiomyocytes	  within	  iPS-­‐derived	  populations	  and	  this	  remarkable	  phenotypic	  preservation	  will	  be	  of	  high	  value	  in	  future	  screens.	  The	  utility	  of	  patient-­‐derived	  cardiomyocytes	  in	  drug	  discovery	  has	  already	  been	  demonstrated	  in	  a	  compound	  screen	  in	  which	  roscovotine,	  a	  cyclin-­‐dependent	  kinase	  inhibitor,	  was	  identified	  as	  an	  indirect	  modifier	  of	  L-­‐type	  Ca2+	  channels	  in	  Timothy	  syndrome-­‐derived	  cardiomyocytes.	  This	  is	  the	  first	  example	  of	  disease-­‐linked	  iPS-­‐derived	  cardiomyocytes	  being	  used	  as	  a	  new	  drug	  screening	  modality	  to	  identify	  a	  novel	  class	  of	  anti-­‐arrhythmic	  75.	  Despite	  the	  substantial	  enthusiasm	  for	  using	  hPSC-­‐derived	  cells	  in	  drug	  screening,	  it	  is	  unlikely	  that	  they	  represent	  a	  ‘cure-­‐all’	  for	  the	  problems	  that	  affect	  the	  CV	  pipeline.	  Clearly,	  there	  is	  a	  limit	  to	  mechanistic	  insights	  into	  contractile	  and	  arrhythmogenic	  dysfunction	  that	  can	  be	  gleaned	  from	  studying	  hPSC-­‐derived	  cardiomyocytes	  (or	  indeed	  any	  cell	  type)	  in	  vitro.	  The	  clinical	  manifestation	  of	  heart	  disease	  is	  influenced	  by	  complex	  genetic,	  epigenetic	  and	  environmental	  factors	  as	  well	  as	  interaction	  with	  other	  organ	  systems	  76	  Accordingly,	  although	  these	  new	  cell-­‐based	  screens	  will	  form	  a	  cornerstone	  of	  CV	  drug	  screening	  strategies	  over	  the	  coming	  years,	  the	  data	  that	  emerges	  from	  them	  must	  be	  interpreted	  in	  the	  context	  of	  outputs	  from	  other	  screening	  systems.	  	   A	  recent	  landmark	  development	  has	  been	  the	  direct	  reprogramming	  of	  differentiated	  fibroblasts	  into	  cardiomyocytes	  without	  reversion	  to	  a	  transient	  pluripotent	  state	  (using	  Gata4,	  Mef2c	  and	  Tbx5)	  77,	  78.	  Cardiomyocytes	  derived	  from	  differentiated	  fibroblasts	  (iCM)	  are	  reported	  to	  functionally	  mature	  over	  several	  weeks	  77,	  but	  unlike	  hPSC	  they	  cannot	  be	  expanded	  in	  culture.	  Thus,	  iCM	  are	  best	  suited	  for	  screening	  strategies	  that	  identify	  factors	  which	  can	  reprogram	  endogenous	  fibroblasts	  (which	  represent	  more	  than	  half	  of	  the	  cell	  population	  in	  the	  adult	  heart)	  into	  functional	  cardiomyocytes	  77.	  Indeed,	  this	  technological	  advance,	  together	  with	  reports	  that	  negate	  the	  concept	  that	  cell	  transplantation	  is	  the	  only	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way	  to	  regenerate	  the	  ageing/failing	  myocardium	  79,	  80	  will	  likely	  focus	  next	  generation	  of	  cardiac	  drug	  screening	  towards	  small	  molecules	  that	  promote	  the	  conversion	  of	  myocardial	  fibroblasts	  directly	  into	  functional	  cardiomyocytes.	  
	  
6.	  From	  cells	  to	  syncitia	  Assays	  using	  single	  cardiomyocytes	  yield	  valuable	  mechanistic	  data	  but	  their	  utility	  in	  the	  context	  of	  CV	  drug	  screening	  is	  compromised	  by	  their	  lack	  of	  functional	  modulation	  by	  neighbouring	  cells.	  Gap	  junction-­‐mediated	  electrotonic	  cell-­‐to-­‐cell	  interactions	  are	  integral	  to	  the	  trans-­‐cellular	  dispersion	  of	  repolarising	  ion	  currents	  and	  thus	  multi-­‐cellular	  platforms	  that	  enable	  individual	  cellular	  behaviour	  to	  be	  evaluated	  in	  the	  context	  of	  functionally	  coupled	  networks	  of	  cells	  are	  a	  cornerstone	  of	  appropriate	  testing	  models.	  	  As	  discussed	  above,	  hPSC-­‐derived	  cardiomyocytes	  form	  beating	  (syncytial)	  clusters	  and	  provide	  a	  cellular	  context	  relevant	  to	  the	  human	  scenario.	  However,	  they	  still	  fall	  short	  of	  recreating	  the	  tissue	  architecture	  characteristic	  of	  the	  situation	  in	  vivo.	  It	  is	  here	  that	  engineered	  heart	  tissue	  (EHT)	  represents	  a	  great	  step	  forward.	  Scaffold-­‐enabled	  EHT	  facilitates	  the	  investigation	  of	  physiologically	  relevant,	  three	  dimensional	  electrical	  (dys)function	  to	  be	  determined	  in	  response	  to	  chemical	  and	  physical	  stimuli	  81,	  82.	  Specifically,	  the	  use	  of	  EHT	  recreates	  the	  much	  greater	  extent	  of	  cell-­‐to-­‐cell-­‐coupling	  characteristic	  of	  the	  
in	  vivo	  scenario.	  These	  meticulous	  experimental	  setups	  promote	  directional	  cell	  alignment	  and	  coupling,	  and	  a	  remarkable	  level	  of	  ultra-­‐structural	  organization	  and	  phenotypic	  competency	  in	  response	  to	  electrical	  and	  mechanical	  cues.	  In	  one	  example,	  neonatal	  rat	  cardiomyocytes	  are	  enmeshed	  in	  a	  mouldable	  fibrin	  matrix	  and	  over	  time	  (15-­‐30	  days)	  the	  cells	  remodel	  this	  hydrogel	  into	  a	  pseudo-­‐cardiomyocyte	  muscle	  strip	  that	  is	  amenable	  to	  specialised	  multi-­‐well	  formats	  83.	  Present	  characterisations	  are	  restricted	  to	  gross	  morphometric	  observations	  of	  rate	  and	  force	  (via	  measurable	  deflections	  of	  silicon	  posts	  embedded	  in	  the	  culture)	  but	  the	  coupling	  of	  EHT	  to	  improved	  imaging	  and	  analytical	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techniques,	  together	  with	  methods	  for	  improving	  cell	  survival	  will	  improve	  their	  utility	  in	  high	  content	  applications	  84.	  Practical	  obstacles	  of	  EHT	  notwithstanding	  (e.g	  proteolytic	  degradation	  of	  the	  hydrogel,	  present	  restriction	  to	  rat	  cells,	  cellular	  phenotypic	  immaturity	  
81),	  EHT	  should	  comprise	  an	  important	  part	  of	  the	  engineered	  armoury	  that	  will	  improve	  CV	  drug	  screening.	  However,	  their	  amenability	  to	  anything	  other	  than	  low-­‐throughput	  applications	  will	  need	  to	  be	  demonstrated.	  	  	  
7.	  From	  syncytia	  to	  organs	  Ventricular	  repolarization,	  defects	  of	  which	  are	  common	  in	  human	  arrhythmias,	  is	  complex	  and	  depends	  on	  the	  density,	  molecular	  specificity	  and	  structural	  arrangement	  of	  ion	  channels	  and	  cell-­‐surface	  receptors.	  These	  factors	  dictate	  the	  regional	  heterogeneity	  of	  the	  myocardium	  85	  that	  governs	  repolarisation	  dispersion	  across	  multiple	  cellular	  layers	  and	  can	  only	  be	  properly	  modelled	  in	  intact	  organs.	  Purkinje	  fibres	  are	  widely	  used	  for	  assessing	  APD	  but	  their	  use	  for	  this	  purpose	  is	  inappropriate	  since	  these	  fibres	  do	  not	  contribute	  to	  the	  QT	  interval	  and	  they	  are	  insensitive	  to	  some	  weaker	  QT	  prolonging	  agents.	  Moreover,	  their	  response	  may	  also	  be	  markedly	  different	  to	  ventricular	  tissue.	  Elsewhere,	  the	  potential	  limitations	  of	  data	  from	  hPSC-­‐derived	  cardiomyocytes	  may	  be	  difficult	  to	  interpret	  properly	  because	  the	  myocardium	  is	  composed	  of	  several	  cell	  types	  in	  defined	  structural	  organisation	  
71.	  The	  niche	  afforded	  to	  organ	  studies	  in	  CV	  drug	  development	  is	  demonstrated	  by	  the	  finding	  that	  repolarization	  gradients	  across	  the	  heart	  dictate	  the	  relative	  pro-­‐	  or	  anti-­‐fibrillatory	  actions	  of	  Na+	  channel	  blockade	  86.	  Similarly,	  the	  efficacy	  of	  a	  new	  lead	  compound	  (AZD1035)	  was	  predicated	  by	  the	  foci	  of	  the	  arrhythmia	  87.	  In	  another	  study,	  Hondeghem	  screened	  over	  700	  repolarisation-­‐delaying	  drugs	  in	  perfused	  rabbit	  hearts	  and	  showed	  that	  the	  ability	  to	  interrogate	  organ-­‐based	  data	  using	  TRIaD	  (triangulation,	  reverse	  use	  dependence,	  AP	  instability	  and	  dispersion)	  revealed	  good	  pro-­‐	  and	  anti-­‐arrhythmogenicity	  indices,	  some	  of	  which	  ran	  counter	  to	  what	  may	  have	  been	  anticipated	  from	  non-­‐organ	  (cellular)	  screens	  88.	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Our	  searches	  did	  not	  reveal	  any	  new	  innovation	  in	  this	  area	  of	  CV	  drug	  screening;	  whether	  this	  reflects	  lack	  of	  development	  or	  that	  current	  modalities	  are	  entirely	  fit	  for	  purpose	  is	  difficult	  to	  ascertain.	  	   	  
8.	  From	  organs	  to	  model	  organisms	  As	  we	  discussed	  in	  Section	  6,	  the	  complex	  mechanisms	  that	  underpin	  the	  initiation	  and	  progression	  of	  cardiac	  dysfunction	  in	  vivo	  restricts	  the	  usefulness	  of	  strategies	  centred	  on	  in	  
vitro	  cell-­‐	  and	  organ	  based	  assays	  in	  CV	  drug	  screening.	  The	  use	  of	  model	  organisms	  enables	  a	  more	  physiologically	  relevant	  context	  for	  the	  profiling	  of	  lead	  compounds,	  including	  the	  ability	  to	  investigate	  their	  effects	  on	  tissues	  other	  than	  the	  heart	  89.	  The	  utility	  of	  mouse	  genetic	  models	  for	  yielding	  rich	  mechanistic	  information	  in	  the	  context	  of	  monogenic	  arrhythmia	  disorders	  arising	  from	  Na+,	  K+	  and	  Ca2+	  ion	  channelopathies	  is	  well	  known.	  Such	  genetic	  models	  of	  cardiac	  contractile	  and	  arrhythmic	  disease	  are	  complemented	  by	  numerous	  small	  animal	  models	  of	  cardiopathology	  especially	  heart	  failure	  induced	  by	  a	  variety	  of	  surgical	  and	  non-­‐surgical	  approaches	  90.	  However,	  from	  a	  physiologic	  perspective	  the	  use	  of	  mouse	  models	  as	  an	  appropriate	  surrogate	  of	  human	  cell	  function	  is	  fundamentally	  flawed;	  heart	  rate	  is	  tenfold-­‐faster	  than	  in	  humans,	  they	  lack	  an	  innate	  propensity	  towards	  arrhythmia	  and	  there	  are	  markedly	  different	  electrophysiological	  bases	  in	  their	  cellular	  action	  potential.	  Consequently,	  these	  species-­‐dependent	  limitations	  have	  led	  the	  pharmaceutical	  industry	  to	  conclude	  that	  the	  mouse	  and	  rat	  heart	  are	  not	  appropriate	  resources	  for	  testing	  arrhythmogenic	  liability	  20.	  Other	  animal	  models	  whose	  cardiac	  physiology	  is	  more	  closely	  aligned	  with	  human	  are	  considered	  more	  appropriate	  (e.g.	  dog,	  guinea	  pig,	  ferret,	  rabbit),	  and	  indeed	  there	  have	  been	  new	  technological	  developments	  that	  enable	  the	  generation	  of	  transgenic	  rabbits	  and	  other	  non-­‐murine	  models	  of	  QT	  prolongation	  91,	  92.	  Again,	  the	  caveat	  is	  that	  these	  do	  not	  faithfully	  recreate	  a	  human-­‐like	  scenario.	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It	  is	  perhaps	  surprising	  that	  in	  view	  of	  the	  need	  to	  make	  animal	  models	  of	  cardiac	  (dys)function	  as	  relevant	  to	  humans	  as	  possible	  that	  the	  zebrafish	  embryo	  model	  is	  gathering	  momentum	  as	  a	  phenotypic	  CV	  drug	  screening	  platform	  93.	  Despite	  the	  obvious	  differences	  in	  CV	  morphology	  and	  anatomy,	  and	  very	  different	  mechanisms	  of	  drug	  bioavailability	  that	  make	  assessments	  of	  drug	  toxicity	  and	  latency	  difficult	  94,	  early	  studies	  in	  zebrafish	  reported	  findings	  that	  could	  plausibly	  be	  extrapolated	  to	  the	  human	  scenario	  95.	  The	  model	  has	  many	  advantages;	  embryos	  are	  transparent,	  easy	  to	  maintain	  and	  highly	  adaptable	  to	  multi-­‐well	  formats	  (3	  embryos	  per	  well	  for	  a	  response	  in	  triplicate!),	  and	  a	  contractile	  atrio-­‐ventricular	  system	  is	  formed	  within	  3	  days	  post-­‐fertilization.	  These	  attributes	  afford	  a	  wealth	  of	  analytical	  techniques	  and	  the	  phenotypic	  assessment	  of	  CV	  (dys)function	  (e.g.	  2:1	  atrio-­‐ventricular	  block)	  can	  be	  augmented	  by	  the	  inclusion	  of	  cellular	  imaging	  using	  fluorescent-­‐based	  techniques.	  	  In	  addition,	  the	  availability	  of	  cardiopathic	  mutants	  such	  as	  reggae	  (mimic	  of	  short	  QT	  syndrome	  and	  ‘pseudo’-­‐AF	  via	  gain	  of	  function	  zebrafish	  ERG	  (zERG)	  channel	  mutation	  (L499P)	  96)	  and	  breakdance	  (QT	  prolongation	  by	  loss-­‐of-­‐function	  I59S	  zERG	  mutation	  38)	  that	  recapitulate	  some	  of	  the	  contractile	  and	  arrhythmogenic	  dysfunction	  characteristic	  of	  the	  human	  genetic	  cardiopathiologies	  97	  augments	  their	  applicability	  to	  CV	  drug	  screens.	  Indeed,	  mutant	  zebrafish	  have	  been	  used	  to	  identify	  flurandrenolide	  (a	  glucocorticoid	  receptor	  ligand)	  and	  a	  compound	  termed	  2MMB	  (unknown	  mode	  of	  action)	  as	  agents	  that	  rescued	  beating	  phenotype	  despite	  not	  rescuing	  the	  trafficking	  defects	  of	  I59S	  zERG	  in	  breakdance	  embryos	  38.	  The	  availability	  of	  libraries	  of	  chemically-­‐mutated	  zebrafish	  (via	  N-­‐ethyl-­‐N-­‐nitrosourea	  (ENU)	  mutagenesis,)	  now	  facilitated	  by	  large-­‐scale	  resources	  such	  as	  those	  at	  the	  Sanger	  Institute	  98,	  will	  further	  enhance	  their	  utility.	  	   Although	  the	  zebrafish	  model	  is	  gaining	  traction	  as	  a	  platform	  for	  early	  stage	  CV	  drug	  screening	  that	  enables	  the	  rapid	  phenotypic	  screen	  of	  a	  large	  number	  of	  compounds,	  their	  use	  is	  not	  without	  problems.	  Firstly,	  the	  absorption	  of	  drugs	  through	  the	  skin	  of	  the	  fish	  is	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critically	  dependent	  on	  their	  physico-­‐chemico	  properties	  and	  this	  makes	  an	  accurate	  assessment	  of	  drug	  potency	  extremely	  difficult.	  Second,	  the	  embryonic	  development	  status	  of	  the	  zebrafish	  may	  predispose	  to	  artefacts	  e.g.	  the	  action	  of	  glucocorticoid	  agonists/antagonists.	  
	  
9.	  Bioinformatics	  From	  Moller	  and	  Slack’s	  excellent	  review	  19,	  it	  seems	  that	  the	  breathless	  pace	  of	  funnelling	  huge	  numbers	  of	  compounds	  into	  assays	  of	  ever	  higher	  throughput	  and	  content	  is	  not	  (so	  far)	  yielding	  breakthrough	  therapies.	  There	  is	  a	  real	  risk	  that	  high	  throughput	  strategies	  will	  lead	  to	  a	  state	  of	  “data	  rich,	  knowledge	  poor”.	  High	  content	  analysis	  (HCA)	  that	  comprises	  multi-­‐parametric	  analysis	  of	  readouts	  from	  cellular	  imaging	  platforms	  requires	  high-­‐end	  programming	  and	  computation	  to	  be	  seamlessly	  integrated	  with	  a	  fundamental	  knowledge	  of	  the	  underlying	  biology.	  Downstream	  deconvolution	  and	  interpretation	  of	  the	  direct	  (and	  indirect)	  outputs	  that	  come	  from	  complex	  high	  content	  screens	  remains	  an	  ongoing	  challenge	  
99.	   In	  parallel	  to	  experimental	  drug	  screening,	  the	  pharmaceutical	  industry	  is	  turning	  to	  sophisticated	  computational	  and	  bibliometric	  methods	  for	  identifying	  novel	  indications	  for	  new	  and	  old	  drugs.	  Systematic	  statistic-­‐based	  screens	  for	  drug-­‐ligand	  interactions	  (‘chemoinformatics’)	  are	  yielding	  valuable	  information	  100	  99	  and	  a	  recent	  article	  proposed	  the	  use	  of	  literature-­‐mining	  methods	  to	  identify	  trends	  in	  drug	  development	  that	  map	  to	  burgeoning	  areas	  of	  mechanistic	  advance	  101.	  These	  approaches	  expand	  our	  horizons	  beyond	  traditional	  and/or	  predictable	  targets	  of	  CV	  drugs	  and	  are	  rendered	  more	  credible	  by	  the	  demonstration	  that	  many	  genetic	  loci	  linked	  to	  QT	  prolongation	  would	  not	  have	  been	  considered	  typical	  CV	  drug	  targets	  102-­‐104.	  However,	  Agarwal’s	  concept	  is	  dependent	  on	  isolated	  pockets	  of	  innovation	  rapidly	  gathering	  momentum	  and	  there	  is	  the	  possibility	  that	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innovators	  of	  true	  value	  are	  lost	  in	  the	  noise	  101.	  There	  is	  also	  a	  more	  general	  concern	  regarding	  an	  over-­‐reliance	  on	  databases	  that	  may	  be	  incomplete	  and/or	  biased.	  	  
10.	  To	  the	  human	  scenario	  Even	  when	  the	  insights	  into	  CV	  disease	  gleaned	  from	  advanced	  molecular,	  cellular	  and	  in	  vivo	  studies	  are	  considered,	  no	  pre-­‐clinical	  assay	  portfolio	  will	  likely	  be	  configured	  that	  replaces	  the	  value	  of	  screening	  lead	  compounds	  in	  large,	  well	  controlled	  clinical	  trials.	  The	  response	  of	  an	  individual	  or	  population	  to	  a	  particular	  drug	  regimen	  is	  so	  complex	  (and	  often	  unpredictable)	  that	  it	  is	  almost	  impossible	  to	  pre-­‐empt	  all	  risk	  at	  the	  pre-­‐clinical	  level.	  Thus,	  for	  all	  our	  understanding	  of	  molecular	  interactivity,	  cell-­‐to-­‐cell	  networks	  and	  pharmacogenomics,	  in	  a	  standard	  clinical	  setting	  the	  propensity	  toward	  ventricular	  fibrillation	  (VF)	  may	  be	  predicated	  by	  ischemic	  episodes	  and	  non-­‐functional	  regions	  of	  the	  myocardium	  or	  pro-­‐arrhythmic	  responses	  to	  systemic	  hypoglycaemia	  105.	  The	  common	  inability	  of	  pre-­‐clinical	  testing	  to	  accurately	  predict	  clinical	  value	  is	  highlighted	  by	  Pfizer’s	  Anthony	  Coyle	  who	  has	  stated	  that	  “In	  vivo	  validation	  has	  zero	  impact,	  in	  most	  cases,	  on	  whether	  you	  will	  be	  successful	  going	  into	  the	  clinic”	  106.	  Below,	  we	  consider	  some	  examples	  that	  highlight	  the	  irreplaceable	  need	  for	  the	  thorough	  clinical	  evaluation	  of	  CV	  drugs.	  	  The	  clinical	  efficacy	  of	  dronedarone,	  a	  non-­‐iodinated	  amiodarone	  derivative,	  is	  critically	  dependent	  on	  pre-­‐existing	  cardiac	  disease.	  It	  is	  proving	  to	  be	  useful	  in	  the	  treatment	  of	  atrial	  fibrillation	  107	  but	  it	  critically	  exacerbates	  cardiac	  dysfunction	  when	  administered	  in	  the	  setting	  of	  heart	  failure	  108.	  The	  mechanistic	  basis	  of	  this	  idiosyncratic	  profile	  remain	  unknown.	  Similarly,	  the	  successful	  re-­‐appropriation	  of	  flecainide	  for	  the	  management	  of	  stress-­‐induced	  arrhythmia	  in	  structurally	  normal	  hearts	  109	  could	  hardly	  have	  been	  predicted	  from	  its	  exceptional	  hazard	  in	  the	  context	  of	  ischemic	  heart	  disease	  110.	  In	  both	  these	  instances,	  the	  dependence	  of	  therapeutic	  efficacy	  on	  the	  pre-­‐existent	  cardiac	  status	  in	  the	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clinical	  scenario	  poses	  real	  and	  often	  intractable	  problems	  for	  those	  configuring	  pre-­‐clinical	  testing	  models.	  Gender	  influences	  numerous	  CV-­‐relevant	  phenomena	  including	  heart	  rate,	  the	  autonomic	  nervous	  system,	  electrolyte	  balance	  and	  the	  susceptibility	  to	  pharmacologic	  perturbation	  of	  the	  QT	  interval.	  The	  susceptibility	  for	  QT	  prolongation	  in	  females	  may	  result	  from	  a	  different	  density	  of	  K+	  channels	  that	  is	  possibly	  due	  to	  hormonal	  regulation	  of	  protein	  transcription/turnover.	  Hepatic	  metabolism	  of	  many	  drugs	  (e.g.	  β-­‐blockers	  111)	  is	  also	  different	  between	  men	  and	  women	  leading	  to	  differential	  bioavailability	  that	  is	  difficult	  to	  predict	  from	  the	  non-­‐human	  testing.	  The	  concept	  that	  an	  individual’s	  genome	  could	  tune	  the	  predisposition	  to	  arrhythmia	  or	  predict	  the	  ultimate	  benefits	  /	  hazards	  of	  a	  specific	  drug	  regime	  underlies	  the	  notion	  of	  genetic	  risk	  in	  the	  population.	  A	  genetic	  predisposition	  that	  re-­‐balances	  a	  drug’s	  safety	  and	  efficacy	  profile	  112,	  may	  be	  underpinned	  by	  common	  DNA	  variants	  termed	  genetic	  polymorphisms.	  Up	  until	  recently	  such	  polymorphisms,	  that	  occur	  in	  both	  intronic	  and	  exonic	  gene	  regions	  and	  may	  or	  may	  not	  produce	  discrete	  changes	  in	  the	  translated	  protein	  sequence,	  were	  considered	  benign	  sequence	  variations	  that	  had	  negligible	  functional	  consequence.	  However	  it	  is	  emerging	  that	  common	  genetic	  polymorphisms	  may	  causally	  modify	  cardiac	  ion	  handling	  and	  impact	  on	  an	  individual’s	  response	  to	  drugs	  113,	  114.	  We	  are	  beginning	  to	  see	  the	  emergence	  of	  this	  complex	  genetic	  heterogeneity	  in	  the	  CV	  patenting	  landscape.	  In	  one	  example,	  a	  common	  polymorphism	  at	  nucleotide	  3308	  in	  the	  SCN5A	  gene	  (encoding	  the	  Nav1.5	  channel)	  results	  in	  an	  amino	  acid	  change	  (S1103Y)	  that	  is	  reported	  to	  predict	  torsadogenic	  liability	  115.	  It	  has	  already	  been	  shown	  that	  another	  polymorphism	  in	  this	  same	  channel	  that	  leads	  to	  the	  H558R	  amino	  acid	  substitution	  modulates	  channel	  function	  16.	  As	  we	  discussed	  above,	  iPS	  cell	  technology	  enables,	  in	  principle,	  drugs	  to	  be	  screened	  in	  the	  context	  of	  an	  individual’s	  genotype.	  Whether	  such	  approaches	  move	  beyond	  technical	  possibility	  into	  a	  feasible	  industrial	  reality	  is	  keenly	  anticipated	  116.	  Recapitulating	  the	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concepts	  from	  Section	  6,	  in	  some	  instances	  genetically-­‐linked	  cardiac	  dysfunction	  is	  precipitated	  by	  non-­‐cardiac	  triggers	  (e.g.	  neuro-­‐humoral	  activation)	  and	  thus	  data	  obtained	  from	  patient-­‐derived	  iPS-­‐cardiomyocytes	  must	  be	  interpreted	  in	  this	  context.	  	  There	  are	  small	  animal	  models	  that	  can	  be	  used	  to	  investigate	  some	  aspects	  of	  sex	  difference	  117,	  118	  and	  background	  genetic	  variation	  119	  but	  the	  limitations	  of	  these	  models	  with	  respect	  to	  their	  relevance	  to	  human	  ion	  handling	  is	  acknowledged.	  	  
	  
11.	  Expert	  Opinion	  and	  concluding	  remarks	  There	  is	  clearly	  an	  urgent	  need	  for	  improved	  pre-­‐clinical	  surveillance	  systems	  that	  enable	  the	  unbiased	  profiling	  of	  the	  safety	  and	  efficacy	  of	  new	  CV	  drugs.	  However,	  the	  CV	  pharmaceutical	  industry	  is	  still	  struggling	  to	  define	  and	  come	  to	  terms	  with	  how	  best	  to	  achieve	  this.	  Within	  contemporary	  screening	  strategies	  there	  are	  sensible	  frameworks	  for	  the	  better	  management	  of	  the	  transition	  between	  stages	  of	  drug	  development	  35	  but	  these	  are	  not	  resulting	  in	  improved	  pipeline	  delivery.	  In	  our	  opinion,	  the	  way	  forward	  necessitates	  new	  modalities	  for	  screening	  drugs	  that	  obviates	  species-­‐dependent	  artefact	  and	  address	  emergent	  concepts	  such	  as	  phenotypic	  screening,	  pharmacogenomics,	  latent	  toxicity,	  cardiomyocyte	  phenotype	  and	  regional	  cardiac	  dysfunction.	  Without	  critically	  re-­‐thinking	  the	  traditional	  tenets	  of	  drug	  screening	  frameworks,	  the	  investment	  in	  ever-­‐higher	  throughput	  methods	  for	  lead	  compound	  identification	  will	  yield	  increasing	  numbers	  of	  compounds	  that	  are	  of	  negligible	  clinical	  value.	  In	  this	  context	  of	  vast	  compound	  library	  screens,	  and	  in	  the	  absence	  of	  frameworks	  with	  better	  abilities	  to	  discriminate	  between	  safe	  and	  effective	  therapy	  and	  hazardous	  off-­‐target	  effects,	  it	  is	  entirely	  possible	  that	  the	  attrition	  rate	  of	  CV	  drugs	  in	  the	  development	  pipeline	  might	  actually	  increase.	  	  There	  are	  no	  easy	  answers	  to	  this	  situation.	  The	  intricacies	  of	  cardiac	  ion	  handling	  and	  its	  modulation	  by	  other	  organ	  systems	  underpin	  the	  fact	  that	  cardiac	  contractility,	  rate	  and	  rhythm	  are	  extraordinarily	  sensitive	  to	  pharmacologic	  perturbation.	  Thus	  the	  keystone	  of	  
EOTP_2011_0055R1 
 22 
next	  generation	  CV	  drug	  screening	  is	  the	  ability	  to	  develop	  new	  systems	  that	  properly	  contextualise	  the	  exquisite	  balance	  between	  effective	  therapy	  and	  hazardous	  side	  effect.	  Presently,	  there	  is	  evidence	  that	  the	  balance	  is	  being	  tipped	  in	  favour	  of	  safety,	  a	  strategy	  that	  may	  paralyse	  CV	  drug	  development.	  Hans-­‐George	  Eichler,	  Senior	  Medical	  Officer	  at	  the	  EMA	  recently	  stated:	  “If	  people	  want	  certainty,	  very	  soon	  we	  will	  not	  have	  any	  new	  drugs”	  120.	  After	  all,	  some	  highly	  effective	  drugs	  (e.g.	  aspirin,	  amiodarone,	  warfarin)	  would	  never	  have	  been	  approved	  in	  today’s	  arguably	  more	  ‘risk-­‐averse’	  environment.	  Conversely,	  using	  sub-­‐optimal	  systems	  for	  assessing	  a	  drug’s	  toxicological	  profile	  is	  fraught	  with	  risk,	  both	  human	  and	  financial.	  Perhaps	  a	  more	  proportional	  sense	  of	  risk-­‐benefit	  profiling	  is	  necessary	  such	  that	  those	  that	  may	  benefit	  from	  a	  specific	  therapeutic	  regime	  are	  not	  disadvantaged	  by	  far-­‐reaching	  “no-­‐go”	  decisions	  121.	  In	  this	  article	  we	  have	  attempted	  to	  highlight	  the	  state	  of	  new	  technological	  and	  methodological	  developments	  relevant	  to	  CV	  drug	  discovery	  and	  validation	  processes	  using	  the	  patent	  literature	  as	  a	  barometer	  of	  innovation.	  From	  the	  outset,	  we	  anticipated	  that	  we	  would	  uncover	  new	  and	  better	  systems	  that	  would	  form	  a	  new	  foundation	  from	  which	  to	  launch	  next	  generation	  CV	  drug	  discovery	  and	  development.	  However,	  apart	  from	  the	  substantial	  momentum	  in	  the	  stem-­‐cell	  and	  cell	  engineering	  fields,	  and	  the	  slow	  emergence	  of	  phenotypic	  screening	  platforms,	  we	  found	  little	  evidence	  of	  truly	  innovative	  solutions	  for	  CV	  drug	  screening	  technologies	  in	  the	  patent	  literature.	  There	  are	  glimpses	  of	  novelty,	  but	  most	  of	  the	  technological	  advances	  described	  in	  patents	  appear	  to	  refine	  and	  develop	  existing	  methods.	  	  This	  apparent	  inability	  (or	  unwillingness?)	  to	  fundamentally	  revamp	  facets	  of	  the	  CV	  drug	  development	  process	  may	  serve	  only	  to	  perpetuate	  the	  failure	  of	  screening	  platforms	  to	  improve	  the	  pipeline.	  	  It	  is	  also	  worth	  noting	  that	  the	  sort	  of	  data	  that	  will	  emerge	  from	  new	  screening	  modalities	  may	  be	  incompatible	  with	  the	  type	  of	  validation	  required	  by	  current	  safety	  mandates.	  Here,	  the	  arguably	  dated	  and	  sometimes	  outmoded	  requirements	  of	  these	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guidelines	  (for	  example	  the	  failure	  to	  appreciate	  the	  importance	  of	  compounds	  that	  shorten	  QT	  and	  place	  too	  much	  emphasis	  on	  blunt	  hERG-­‐blocking	  profiles)	  must	  be	  updated	  to	  become	  entirely	  relevant	  to	  the	  way	  in	  which	  CV	  drug	  screening	  must	  be	  developed	  in	  order	  to	  reduce	  the	  presently	  unacceptable	  pre-­‐clinical	  attrition	  and	  clinical	  problems	  associated	  with	  a	  disproportionate	  number	  of	  lead	  compounds.	  As	  a	  corollary,	  the	  future	  emergence	  of	  new	  technologies	  and	  resources	  does	  not	  guarantee	  that	  they	  will	  be	  appropriate	  tools	  for	  next	  generation	  CV	  drug	  screening.	  Emerging	  cell-­‐based	  platforms,	  high	  content	  analysis,	  bioinformatics	  approaches	  and	  physiologic	  testing	  must	  be	  rigorously	  validated	  to	  demonstrate	  an	  absolute	  relevance	  and	  usefulness	  of	  purpose	  in	  this	  new	  era.	  According	  to	  Titus	  Livy,	  "In	  difficult	  and	  hopeless	  situations	  the	  boldest	  plans	  are	  the	  safest".	  The	  pharmaceutical	  industry	  needs	  to	  be	  bold	  and	  resourceful	  if	  it	  is	  to	  reinvigorate	  its	  CV	  pipeline;	  the	  situation	  is	  difficult	  but	  it	  is	  not	  yet	  hopeless.	  	  





Figure.	  Patent	  search	  strategy	  and	  information	  profiling.	  
a	  ESP@CENET	  does	  not	  enable	  full	  text	  searching.	  
b	  Only	  those	  patents	  that	  had	  been	  granted	  (i.e.	  B	  status)	  were	  considered	  and	  any	  relating	  to	  natural	  and	  synthetic	  pharmacology,	  devices,	  medicinal	  agents	  and	  DNA	  variants	  (except	  common	  sequence	  polymorphisms)	  were	  excluded.	  	  




References	  1.	   George	  CH,	  Barberini-­‐Jammaers	  SR,	  Muller	  CT.	  Refocussing	  therapeutic	  strategies	  for	  cardiac	  arrhythmias:	  defining	  viable	  molecular	  targets	  to	  restore	  cardiac	  ion	  flux.	  Expert	  Opin	  Ther	  Patents	  2008;18:1-­‐19.	  2.	   http://www.fda.gov/Drugs/default.htm.	  3.	   Savelieva	  I,	  Camm	  J.	  Anti-­‐arrhythmic	  drug	  therapy	  for	  atrial	  fibrillation:	  current	  anti-­‐arrhythmic	  drugs,	  investigational	  agents	  and	  innovative	  approaches.	  Europace	  2008;10:647-­‐65.	  4.	   Landmesser	  U,	  Wollert	  KC,	  Drexler	  H.	  Potential	  novel	  pharmacological	  therapies	  for	  myocardial	  remodelling.	  Cardiovasc	  Res	  2009;81:519-­‐27.	  5.	   Nattel	  S,	  Carlsson	  L.	  Innovative	  approaches	  to	  anti-­‐arrhythmic	  drug	  therapy.	  Nat	  Rev	  Drug	  Disc	  2006;5:1034-­‐49.	  6.	   Mason	  PK,	  DiMarco	  JP.	  New	  pharmacological	  agents	  for	  arrhythmias.	  Circ	  Arrhythmia	  Electrophysiol	  2009;2:588-­‐97.	  7.	   Mukherjee	  D,	  Nissen	  SE,	  Topol	  EJ.	  Risk	  of	  cardiovasular	  events	  associated	  with	  selecitve	  COX-­‐2	  inhiibitors.	  JAMA	  2001;286:954-­‐59.	  8.	   Bowe	  C.	  Vioxx	  storm	  to	  have	  lasting	  effects.	  Financial	  Times	  2007;November	  12.	  9.	   Nissen	  SE,	  Wolski	  K.	  Effect	  of	  rosiglitazone	  on	  the	  risk	  of	  myocardial	  infarction	  and	  death	  from	  cardiovascular	  causes.	  N	  Engl	  J	  Med	  2007;356:2457-­‐2471.	  10.	   Masoudi	  FA.	  Improving	  drug	  safety	  surveillance:	  lessons	  from	  rosiglitazone.	  Circ	  Cardiovasc	  Qual	  Outcomes	  2010;3:444-­‐46.	  11.	   Chong	  CR,	  Sullivan	  DJ.	  New	  uses	  for	  old	  drugs.	  Nature	  2007;448:645-­‐46.	  12.	   http://www.uspto.gov/.	  13.	   http://www.epo.org/searching/free/espacenet.html.	  14.	   Netzer	  R,	  Pongs	  O.	  Novel	  tension-­‐dependent	  potassium	  channel	  and	  the	  use	  thereof	  in	  the	  development	  of	  new	  therapeutic	  agents.	  EP1102847	  2008.	  15.	   Milting	  H,	  Lukas	  N,	  Klauke	  B,	  et	  al.	  Composite	  polymorphisms	  in	  the	  ryanodine	  receptor	  2	  gene	  associated	  with	  arrhythmogenic	  right	  ventricular	  cardiomyopathy.	  Cardiovasc	  Res	  2006;71:496-­‐505.	  16.	   Poelzing	  S,	  Forleo	  C,	  Samodell	  M,	  et	  al.	  SCN5A	  polymorphism	  restores	  trafficking	  of	  a	  Brugada	  syndrome	  mutation	  on	  a	  separate	  gene.	  Circulation	  2006;114:368-­‐75.	  17.	   Farkas	  AS,	  Nattel	  S.	  Minimizing	  repolarization-­‐related	  proarrhythmic	  risk	  in	  drug	  development	  and	  clinical	  practice.	  Drugs	  2010;70:573-­‐603.	  18.	   Nattel	  S,	  Duker	  G,	  Carlsson	  L.	  Model	  systems	  for	  the	  discovery	  and	  development	  of	  antiarrhythmic	  drugs.	  Prog	  Biophys	  Mol	  Biol	  2008;98:328-­‐39.	  19.	   Moller	  C,	  Slack	  M.	  Impact	  of	  new	  technologies	  for	  cellular	  screening	  along	  the	  drug	  value	  chain.	  Drug	  Discovery	  Today	  2010;15:384-­‐90.	  **	  Refs.	  17-­‐19	  provide	  excellent	  overviews	  of	  contemporary	  drug	  screening	  modalities	  	  20.	   http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002841.pdf	  21.	   http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/guidances/default.htm.	  2011.	  22.	   Lindgren	  S,	  Bass	  AS,	  Briscoe	  R,	  et	  al.	  Benchmarking	  safety	  pharmacology	  regulatory	  packages	  and	  best	  practice.	  J	  Pharmacol	  Toxicol	  Meth	  2008;58:99-­‐109.	  23.	   Lu	  HR,	  Vlaminckx	  E,	  Hermans	  AN,	  et	  al.	  Predicting	  drug-­‐induced	  changes	  in	  QT	  interval	  and	  arrhythmias:	  QT-­‐drugs	  point	  to	  gaps	  in	  the	  ICHS7B	  guidelines.	  Br	  J	  Pharmacol	  2008;154:1427-­‐38.	  
EOTP_2011_0055R1 
 26 
24.	   Witchel	  HJ,	  MIlnes	  JT,	  Mitcheson	  JS,	  et	  al.	  Troubleshooting	  problems	  with	  in	  vitro	  screening	  of	  drugs	  for	  QT	  interval	  prolongation	  using	  HERG	  K+	  channels	  expressed	  in	  mammalian	  cell	  lines	  and	  Xenopus	  oocytes.	  J	  Pharmacol	  Toxicol	  Meth	  2002;48:65-­‐80.	  25.	   Maher	  MP,	  Gonzalez	  III	  JE.	  High	  throughput	  method	  and	  system	  for	  screening	  candidate	  compounds	  for	  activity	  against	  target	  ion	  channels.	  US7176016	  2007.	  26.	   Vasylyev	  DV,	  Merrill	  TL,	  Bowlby	  MR,	  et	  al.	  Perfusion	  system	  and	  apparatus	  for	  automated	  multi-­‐channel	  patch-­‐clamp	  recordings	  utilizing	  inside-­‐out	  whole-­‐cell	  configuration.	  US7465558	  2008.	  27.	   Yan	  G-­‐X.	  Methods	  for	  screening	  compounds	  for	  proarrhythmic	  risk	  and	  antiarrhythmic	  efficacy.	  US7396524	  2008.	  28.	   Owen	  DG,	  Byrne	  NG.	  High	  throughput	  screen.	  EP1621888	  2009.	  29.	   Adorante	  JS,	  Ehring	  GR.	  High-­‐throughput	  screen	  for	  identifying	  selective	  persistent	  sodium	  channels	  channel	  blockers.	  US7754440	  2010.	  30.	   Brown	  AM,	  Ficker	  E,	  Wible	  BA.	  High	  throughput	  assay	  systems	  and	  methods	  for	  identifying	  agents	  that	  alter	  expression	  of	  cellular	  proteins.	  US7678548	  2010.	  31.	   Mendrick	  DL,	  Porter	  MW,	  Johnson	  KR,	  et	  al.	  Molecular	  cardiotoxicology	  modeling.	  US7447594	  2008.	  32.	   James	  JF,	  Hewett	  TE,	  Robbins	  J.	  Cardiac	  physiology	  in	  transgenic	  mice.	  Circ	  Res	  1998;82:407-­‐15.	  33.	   Redfern	  WS,	  Carlsson	  L,	  Davis	  AS,	  et	  al.	  Relationships	  between	  preclinical	  cardiac	  electrophysiology,	  clinical	  QT	  interval	  prolongation	  and	  torsade	  de	  pointes	  for	  a	  broad	  range	  of	  drugs:	  evidence	  for	  a	  provisional	  safety	  margin	  in	  drug	  development.	  Cardiovasc	  Res	  2003;58:32-­‐45.	  *	  A	  useful	  comparision	  of	  the	  'safety'	  profiles	  of	  some	  important	  anti-­‐arrhythmic	  compounds	  	  34.	   Witchel	  HJ.	  Drug-­‐induced	  hERG	  block	  and	  long	  QT	  syndrome.	  Cardiovasc	  Ther	  2011;29:251-­‐259.	  35.	   Haverkamp	  W,	  Breithardt	  G,	  Camm	  AJ,	  et	  al.	  The	  potential	  for	  QT	  prolongation	  and	  proarrhythmia	  by	  non-­‐antiarrhythmic	  drugs:	  clinical	  and	  regulatory	  implications.	  Eur	  Heart	  J	  2001;3	  Supp	  K:81-­‐89.	  36.	   Moller	  C.	  Keeping	  the	  rhythm:	  hERG	  and	  beyond	  in	  cardiovascular	  safety	  pharmacology.	  Expert	  Rev	  Clin	  Pharmacol	  2010;3:321-­‐29.	  37.	   Kowey	  PR,	  Malik	  M.	  The	  QT	  interval	  as	  it	  relates	  to	  the	  safety	  on	  non-­‐cardiac	  drugs.	  Eur	  Heart	  J	  2007;9	  Supp	  G:G3-­‐G8.	  38.	   Peal	  DS,	  Mills	  RW,	  Lynch	  SN,	  et	  al.	  Novel	  chemical	  suppressors	  of	  long	  QT	  syndrome	  identified	  by	  an	  in	  vivo	  functional	  screen.	  Circulation	  2011;123:23-­‐30.	  *	  Use	  of	  a	  zebrafish	  embryo-­‐based	  phenotypic	  screen	  to	  identify	  novel	  modulators	  of	  hERG	  	  39.	   Roth	  BL,	  Sheffler	  DJ,	  Kroeze	  WK.	  Magic	  shotguns	  versus	  magic	  bullets:	  selectively	  non-­‐selective	  drugs	  for	  moods	  disorders	  and	  schizophrenia.	  Nat	  Rev	  Drug	  Disc	  2004;3:353-­‐59.	  40.	   Rosen	  MR,	  Robinson	  RB,	  Cohen	  IS,	  et	  al.	  High	  throughput	  biological	  heart	  rate	  monitor	  that	  is	  molecularly	  determined.	  US7122307	  2006.	  41.	   Takahashi	  K,	  Yamanaka	  S.	  Induction	  of	  pluripotent	  stem	  cells	  from	  mouse	  embryonic	  and	  adult	  fibroblast	  cultures	  by	  defined	  factors.	  Cell	  2006;126:663-­‐76.	  	  **	  A	  seminal	  description	  of	  the	  stunning	  technical	  feat	  of	  reprogramming	  mouse	  somatic	  cells	  into	  pluripotent	  stem	  cells.	  	  42.	   Takahashi	  H,	  Tanabe	  K,	  Ohnuki	  M,	  et	  al.	  Induction	  of	  pluripotent	  stem	  cells	  from	  adult	  human	  fibroblasts	  by	  defined	  factors.	  Cell	  2007;131:861-­‐72.	  43.	   Yu	  J,	  Vodyanik	  MA,	  Smuga-­‐Otoo	  K,	  et	  al.	  Induced	  pluripotent	  stem	  cell	  lines	  derived	  from	  human	  somatic	  cells.	  Science	  2007;318:1917-­‐20.	  
EOTP_2011_0055R1 
 27 
44.	   Park	  I-­‐H,	  Zhao	  R,	  West	  JA,	  et	  al.	  Reprogramming	  of	  human	  somatic	  cells	  to	  pluripotency	  with	  defined	  factors.	  Nature	  2008;451:141-­‐46.	  **	  Refs.	  42-­‐44	  describe	  the	  reprogramming	  of	  human	  somatic	  cells	  into	  iPSC.	  	  45.	   Zhang	  J,	  Wilson	  GF,	  Soerens	  AG,	  et	  al.	  Functional	  cardiomyocytes	  derived	  from	  human	  induced	  pluripotent	  stem	  cells.	  Circ	  Res	  2009;104:e30-­‐e41.	  **	  The	  first	  partial	  electrophysiological	  and	  cellular	  characterisation	  of	  cardiomyocytes	  derived	  from	  human	  iPS	  cells.	  	  46.	   Not	  assigned.	  Embryonic	  stem	  cells	  produced	  via	  embryo	  destruction	  are	  not	  patentable.	  Nat	  Rev	  Drug	  Disc	  2011;10:330.	  47.	   Cyranoski	  D.	  Japan	  fast-­‐tracks	  stem-­‐cell	  patent.	  Nature	  2008;455:269.	  48.	   Cyranoski	  D.	  Japan	  ramps	  up	  patent	  effort	  to	  keep	  iPS	  lead.	  Nature	  2008;453:962-­‐63.	  49.	   Webb	  S.	  The	  gold	  rush	  for	  induced	  pluripotent	  stem	  cells.	  Nat	  Biotech	  2009;27:977-­‐79.	  50.	   Yamanaka	  S.	  Method	  for	  producing	  induced	  pluripotent	  stem	  cell.	  JP2008283972	  2008.	  51.	   Sakurada	  K,	  Masaki	  H,	  Ishikawa	  T.	  Human	  pluripotent	  stem	  cells	  and	  their	  medical	  use.	  GB2450603	  2010.	  52.	   Jaenisch	  R,	  Hochedlinger	  K.	  Methods	  for	  reprogramming	  somatic	  cells.	  US7682828	  2010.	  53.	   Thomson	  JA,	  Kamp	  TJ,	  Ma	  Y,	  et	  al.	  Functional	  cardiomyocytes	  from	  human	  embryonic	  stem	  cells.	  US7611852	  2009.	  54.	   Xu	  C,	  Gold	  JD.	  Process	  for	  making	  transplantable	  cardiomyocytes	  from	  human	  embrynonic	  stem	  cells.	  US7732199	  2010.	  55.	   Murry	  CE,	  Laflamme	  MA.	  Formulation	  to	  improve	  survival	  of	  tranplanted	  cells.	  US7875451	  2011.	  56.	   Zon	  LI,	  Davidson	  AJ,	  Daley	  GQ.	  Method	  of	  enhancing	  proliferation	  and/or	  hematopoietic	  differentiation	  of	  stem	  cells.	  US7427603	  2008.	  57.	   Kaji	  K,	  Norrby	  K,	  Paca	  A,	  et	  al.	  Virus-­‐free	  induction	  of	  pluripotency	  and	  subsequent	  excision	  of	  reprogramming	  factors.	  Nature	  2009;458:771-­‐75.	  58.	   Kim	  D,	  Kim	  C-­‐H,	  Moon	  J-­‐I,	  et	  al.	  Generation	  of	  human	  induced	  pluripotent	  stem	  cells	  by	  direct	  delivery	  of	  reprogramming	  proteins.	  Cell	  Stem	  Cell	  2009;4:472-­‐76.	  59.	   Chien	  KR.	  Regenerative	  medicine	  and	  human	  models	  of	  human	  disease.	  Nature	  2008;453:302-­‐05.	  60.	   Passier	  R,	  van	  Laake	  LW,	  Mummery	  CL.	  Stem-­‐cell-­‐based	  therapy	  and	  lessons	  from	  the	  heart.	  Nature	  2008;453:322-­‐29.	  61.	   Braam	  SR,	  Passier	  R,	  Mummery	  CL.	  Cardiomyocytes	  from	  human	  pluripotent	  stem	  cells	  in	  regenerative	  medicine	  and	  drug	  discovery.	  Trends	  Pharm	  Sci	  2009;30:536-­‐45.	  62.	   Kim	  K,	  Doi	  A,	  Wen	  B,	  et	  al.	  Epigenetic	  memory	  in	  induced	  pluripotent	  stem	  cells.	  Nature	  2010;467:285-­‐90.	  63.	   Zwaka	  TP.	  Troublesome	  memories.	  Nature	  2010;437:280-­‐81.	  64.	   Gore	  A,	  Li	  Z,	  Fung	  H-­‐L,	  et	  al.	  Somatic	  coding	  mutations	  in	  human	  induced	  pluripotent	  stem	  cells.	  Nature	  2011;471:63-­‐67.	  65.	   Lister	  R,	  Pelizzola	  M,	  Kida	  YS,	  et	  al.	  Hotspots	  of	  aberrant	  epigenomic	  reprogramming	  in	  human	  induced	  pluripotent	  stem	  cells.	  Nature	  2011;471:68-­‐73.	  *	  Ref.	  62-­‐65	  highlight	  that	  the	  epigenetic	  abnormalities	  in	  reprogrammed	  iPS	  cells	  probably	  restricts	  their	  immediate	  commercial	  niche	  to	  in	  vitro	  drug	  screening	  platforms.	  	  66.	   McNeish	  J.	  Embryonic	  stem	  cells	  in	  drug	  discovery.	  Nat	  Rev	  Drug	  Disc	  2004;3:70-­‐80.	  67.	   Pouton	  C,	  Haynes	  JM.	  Embryonic	  stem	  cells	  as	  a	  source	  of	  models	  for	  drug	  discovery.	  Nat	  Rev	  Drug	  Disc	  2007;6:605-­‐16.	  
EOTP_2011_0055R1 
 28 
68.	   Dick	  E,	  Rajamohan	  D,	  Ronksley	  J,	  et	  al.	  Evaluating	  the	  utility	  of	  cardiomyocytes	  from	  human	  pluripotent	  stem	  cells	  for	  drug	  screening.	  Biochem	  Soc	  Trans	  2010;38:1037-­‐45.	  69.	   Yokoo	  N,	  Baba	  S,	  Kaichi	  S,	  et	  al.	  The	  effects	  of	  cardioactive	  drugs	  on	  cardiomyocytes	  derived	  from	  human	  induced	  pluripotent	  stem	  cells.	  Biochem	  Biophys	  Res	  Commun	  2009;387:482-­‐88.	  *	  An	  early,	  very	  low	  complexity	  use	  of	  human	  iPS-­‐derived	  cardiomyocytes	  in	  drug	  screening.	  	  70.	   Laflamme	  MA,	  Chen	  KY,	  Naumova	  AV,	  et	  al.	  Cardiomyocytes	  derived	  from	  human	  embryonic	  stem	  cells	  in	  pro-­‐survival	  factors	  enhance	  function	  of	  infarcted	  rat	  hearts.	  Nat	  Biotech	  2007;25:1015-­‐24.	  71.	   Dambrot	  C,	  Passier	  R,	  Atsma	  D,	  et	  al.	  Cardiomyocyte	  differentiation	  of	  pluripotent	  stem	  cells	  and	  their	  use	  as	  cardiac	  disease	  models.	  Biochem	  J	  2011;434:25-­‐35.	  72.	   Moretti	  A,	  Bellin	  M,	  Welling	  A,	  et	  al.	  Patient-­‐specific	  induced	  pluripotent	  stem-­‐cell	  models	  for	  Long-­‐QT	  syndrome.	  N	  Engl	  J	  Med	  2010;363:1397-­‐409.	  **	  A	  ground-­‐breaking	  study	  showing	  that	  iPS-­‐derived	  cardiomyocytes	  from	  LQT-­‐affected	  individuals	  recapitulate	  disease-­‐linked	  cellular	  and	  electrophysiological	  abnormalities.	  	  73.	   Itzhaki	  I,	  Maizels	  L,	  Huber	  I,	  et	  al.	  Modelling	  the	  long	  QT	  syndrome	  with	  induced	  pluripotent	  stem	  cells.	  Nature	  2011;471:225-­‐229.	  74.	   Matsa	  E,	  Rajamohan	  D,	  Dick	  E,	  et	  al.	  Drug	  evaluation	  in	  cardiomyocytes	  derived	  from	  human	  induced	  pluripotent	  stem	  cells	  carrying	  a	  long	  QT	  syndrome	  type	  2	  mutation.	  Eur	  Heart	  J	  2011;32:952-­‐62.	  75.	   Yazawa	  M,	  Hseuh	  B,	  Jia	  X,	  et	  al.	  Using	  induced	  pluripotent	  stem	  cells	  to	  investigate	  cardiac	  phenotypes	  in	  Timothy	  Syndrome.	  Nature	  2011;471:230-­‐234.	  76.	   Samuels	  MA.	  The	  Brain-­‐Heart	  Connection.	  Circulation	  2007;116:77-­‐84.	  77.	   Ieda	  M,	  Fu	  J-­‐D,	  Delgado-­‐Olguin	  P,	  et	  al.	  Direct	  reprogamming	  of	  fibroblasts	  into	  functional	  cardiomyocytes	  by	  defined	  factors.	  Cell	  2010;142:375-­‐86.	  **	  A	  step-­‐change	  in	  cellular	  reprogramming.	  Ieda	  and	  colleagues	  demonstrate	  that	  functional	  cardiomyocytes	  can	  be	  induced	  from	  mouse	  fibroblasts	  without	  the	  intermediate	  pluripotent	  step.	  	  78.	   Efe	  JA,	  Hilcove	  S,	  Kim	  J,	  et	  al.	  Conversion	  of	  mouse	  fibroblasts	  into	  cardiomyocytes	  using	  a	  direct	  reprogramming	  strategy.	  Nat	  Cell	  Biol	  2011;13:215-­‐222.	  79.	   Angert	  D,	  Berretta	  RM,	  Kubo	  H,	  et	  al.	  Repair	  of	  the	  injured	  adult	  heart	  involves	  new	  myocytes	  potentially	  derived	  from	  resident	  cardiac	  stem	  cells.	  Circ	  Res	  2011;108:1226-­‐37.	  80.	   Kajstura	  J,	  Urbanek	  K,	  Perl	  S,	  et	  al.	  Cardiomyogenesis	  in	  the	  adult	  human	  heart.	  Circ	  Res	  2010;107:305-­‐15.	  81.	   Hansen	  A,	  Eder	  A,	  Bonstrup	  M,	  et	  al.	  Development	  of	  a	  drug	  screening	  platform	  based	  on	  engineered	  heart	  tissue.	  Circ	  Res	  2010;107:35-­‐44.	  82.	   Tandon	  N,	  Cannizzaro	  C,	  Chao	  P-­‐HG,	  et	  al.	  Electrical	  stimulation	  systems	  for	  cardiac	  tissue.	  Nat	  Protocols	  2009;4:155-­‐73.	  83.	   Zimmerman	  WH,	  Eschenhagen	  T.	  Multiloop	  engineered	  heart	  muscle	  tissue.	  EP1963489	  2010.	  84.	   Madry	  H,	  Vunjak-­‐Novakovic	  G,	  Trippel	  SB,	  et	  al.	  Tissue	  engineering	  enhanced	  by	  the	  transfer	  of	  a	  growth	  factor	  gene.	  US7252982	  2007.	  85.	   Kang	  G,	  Giovannone	  SF,	  Liu	  N,	  et	  al.	  Purkinje	  cells	  from	  RyR2	  mutant	  mice	  are	  highly	  arrhythmogenic	  but	  responsive	  to	  targeted	  therapy.	  Circ	  Res	  2010;107:512-­‐19.	  86.	   Coronel	  R,	  Wilms-­‐Schopman	  JG,	  Janse	  MJ.	  Anti-­‐	  or	  profibrillatory	  effects	  of	  Na+	  channel	  blockade	  depend	  on	  the	  site	  of	  application	  relative	  to	  gradients	  in	  repolarization.	  Front.	  Physiol.	  2010;1:1-­‐9.	  
EOTP_2011_0055R1 
 29 
*	  An	  interesting	  study	  that	  warns	  of	  the	  limitations	  of	  two-­‐dimensional,	  low	  complexity	  cell-­‐culture-­‐based	  systems	  in	  determining	  the	  actions	  of	  specific	  drug	  classes.	  	  87.	   Sicouri	  S,	  Carlsson	  L,	  Antzelevitch	  C.	  Electrophysiologic	  and	  antiarrhythmic	  effects	  of	  AZD1305	  in	  canine	  pulmonary	  vein	  sleeves.	  J	  Pharm	  Exp	  Ther	  2010;334:255-­‐59.	  88.	   Hondeghem	  LM,	  Carlsson	  L,	  Duker	  G.	  Instability	  and	  triangulation	  of	  the	  action	  potential	  predict	  serious	  proarrhythmia,	  but	  action	  potential	  duration	  prolongation	  is	  antiarrhythmic.	  Circulation	  2001;103:2004-­‐13.	  89.	   Bassingthwaighte	  J,	  Hunter	  P,	  Noble	  D.	  The	  cardiac	  physiome:	  perspectives	  for	  the	  future.	  Exp	  Physiol	  2009;94.5:597-­‐605.	  90.	   Patten	  RD,	  Hall-­‐Porter	  MR.	  Small	  animal	  models	  of	  heart	  failure:	  development	  of	  novel	  therapies,	  past	  and	  present.	  Circ	  Heart	  Fail	  2009;2:138-­‐44.	  91.	   Brunner	  M,	  Peng	  X,	  Liu	  G-­‐X,	  et	  al.	  Mechanisms	  of	  cardiac	  arrhythmias	  and	  sudden	  death	  in	  transgenic	  rabbits	  with	  long	  QT	  syndrome.	  J	  Clin	  Invest	  2008;118:2246-­‐59.	  92.	   Koren	  G,	  Peng	  X,	  Mathur	  R,	  et	  al.	  Animal	  models	  of	  long	  QT	  syndrome	  and	  uses	  thereof.	  US7718846	  2010.	  93.	   MacRae	  CA,	  Milan	  DJ,	  Burns	  CG,	  et	  al.	  Zebrafish	  assay.	  US7465848	  2008.	  94.	   Rubinstein	  AL.	  Zebrafish	  assays	  for	  drug	  toxicity	  screening.	  Expert	  Opin	  Drug	  Metab	  Toxicol	  2006;2:231-­‐40.	  95.	   Milan	  DJ,	  Peterson	  TA,	  Ruskin	  JN,	  et	  al.	  Drugs	  that	  induce	  repolarization	  abnormalities	  cause	  bradycardia	  in	  zebrafish.	  Circulation	  2003;107:1355-­‐58.	  96.	   Hassel	  D,	  Scholz	  EP,	  Trano	  N,	  et	  al.	  Deficient	  zebrafish	  ether-­‐a-­‐go-­‐go-­‐related	  gene	  channel	  gating	  causes	  short-­‐QT	  syndrome	  in	  zebrafish	  reggae	  mutants.	  Circulation	  2008;117:866-­‐75.	  97.	   Sehnert	  A,	  Stainier	  DYR.	  A	  window	  to	  the	  heart:	  can	  zebrafish	  mutants	  help	  us	  understand	  heart	  disease	  in	  humans?	  Trends	  Genet	  2002;18:491-­‐94.	  98.	   http://www.sanger.ac.uk/Projects/D_rerio/mutres/.	  99.	   Chan	  JNY,	  Nislow	  C,	  Emili	  A.	  Recent	  advances	  and	  method	  development	  for	  drug	  target	  identification.	  Trends	  Pharm	  Sci	  2009;31:82-­‐88.	  100.	   Keiser	  MJ,	  Setola	  V,	  Irwin	  JJ,	  et	  al.	  Predicting	  new	  molecular	  targets	  for	  known	  drugs.	  Nature	  2009;462:175-­‐81.	  101.	   Agarwal	  P,	  Searls	  DB.	  Can	  literature	  analysis	  identify	  innovation	  drivers	  in	  drug	  discovery.	  Nat	  Rev	  Drug	  Disc	  2009;8:865-­‐78.	  102.	   Newton-­‐Cheh	  C,	  Eijgelsheim	  M,	  Rice	  KM,	  et	  al.	  Common	  variants	  at	  ten	  loci	  influence	  QT	  interval	  duration	  in	  the	  QTGEN	  Study.	  Nat	  Genet	  2009;41:399-­‐406.	  103.	   Pfeufer	  A,	  Sanna	  S,	  Arking	  DE,	  et	  al.	  Common	  variants	  at	  ten	  loci	  modulate	  the	  QT	  interval	  duration	  in	  the	  QTSCD	  Study.	  Nat	  Genet	  2009;41:407-­‐14.	  104.	   Sotoodehnia	  N,	  al	  e.	  Common	  variants	  in	  22	  loci	  are	  associated	  with	  QRS	  duration	  and	  cardiac	  ventricular	  conduction.	  Nat	  Genet	  2010;42:1068-­‐76.	  105.	   Nordin	  C.	  The	  case	  for	  hypoglycaemia	  as	  a	  proarrhythmic	  event:	  basic	  and	  clinical	  evidence.	  Diabetologia	  2010;53:1552-­‐61.	  106.	   Ratner	  M.	  Pfizer	  reaches	  out	  to	  academia-­‐	  again.	  Nat	  Biotech	  2010;29:3-­‐4.	  107.	   Hohnloser	  SH,	  Crijns	  HJGM,	  van	  Eickels	  M,	  et	  al.	  Effect	  of	  dronedarone	  on	  cardiovascular	  events	  in	  atrial	  fibrillation.	  N	  Engl	  J	  Med	  2009;360:668-­‐78.	  108.	   Kober	  L,	  Torp-­‐Pedersen	  C,	  McMurray	  JJV,	  et	  al.	  Increased	  mortality	  after	  dronedarone	  therapy	  for	  severe	  heart	  failure.	  N	  Engl	  J	  Med	  2008;358:2678-­‐87.	  109.	   Watanabe	  H,	  Chopra	  N,	  Laver	  D,	  et	  al.	  Flecainide	  prevents	  catecholaminergic	  polymorphic	  ventricular	  tachycardia	  in	  mice	  and	  humans.	  Nat	  Med	  2009;15:380-­‐83.	  110.	   Echt	  DS,	  Liebson	  PR,	  Mitchell	  LB,	  et	  al.	  Mortality	  and	  morbidity	  in	  patient	  receiving	  encainide,	  flecainide,	  or	  placebo.	  The	  Cardiac	  Arrhythmia	  Suppression	  Trial.	  N	  Engl	  J	  Med	  1991;324:781-­‐84.	  	  
EOTP_2011_0055R1 
 30 
*	  Refs.	  107-­‐110	  highlight	  that	  diverse	  outcomes	  of	  a	  specific	  therapeutic	  regime	  may	  be	  critically	  dependent	  on	  pre-­‐existent	  cardiac	  status.	  	  111.	   Drici	  M-­‐D,	  Clement	  N.	  Is	  gender	  a	  risk	  factor	  for	  adverse	  drug	  reactions?	  The	  example	  of	  drug-­‐induced	  long	  QT	  syndrome.	  Drug	  Safety	  2001;24:575-­‐85.	  112.	   Roden	  DM.	  Proarrhythmia	  as	  a	  pharmacogenomic	  entity:	  a	  critical	  review	  and	  formulation	  of	  a	  unifying	  hypothesis.	  Cardiovasc	  Res	  2005;67:419-­‐25.	  113.	   Liggett	  SB,	  Cresci	  S,	  Kelly	  RJ,	  et	  al.	  A	  GRK5	  polymorphism	  that	  inhibits	  ß-­‐adrenergic	  receptor	  signaling	  is	  protective	  in	  heart	  failure.	  Nat	  Med	  2008;14:510-­‐17.	  114.	   Sotoodehnia	  N,	  Siscovick	  DS,	  Vatta	  M,	  et	  al.	  B2-­‐adrenergic	  receptor	  genetic	  variants	  and	  risk	  of	  sudden	  cardiac	  death.	  Circulation	  2006;113:1842-­‐48.	  115.	   Keating	  MT,	  Splawski	  I.	  Common	  polymorphism	  in	  SCN5A	  implicated	  in	  drug-­‐induced	  cardiac	  arrhythmia.	  US7208273	  2007.	  116.	   Hamburg	  MA,	  Collins	  FS.	  The	  path	  to	  personalized	  medicine.	  N	  Engl	  J	  Med	  2010;363:301-­‐304.	  117.	   Brouillette	  J,	  Rivard	  K,	  Lizotte	  E,	  et	  al.	  Sex	  and	  strain	  differences	  in	  adult	  mouse	  cardiac	  repolarization:	  importance	  of	  androgens.	  Cardiovasc	  Res	  2005;65:148-­‐57.	  118.	   Mason	  SA,	  MacLeod	  KT.	  Cardiac	  action	  potential	  duration	  and	  calcium	  regulation	  in	  males	  and	  females.	  Biochem	  Biophys	  Res	  Commun	  2009;388:565-­‐70.	  119.	   Shah	  AP,	  Siedlecka	  U,	  Gandhi	  A,	  et	  al.	  Genetic	  background	  affects	  function	  and	  intracellular	  calcium	  regulation	  of	  mouse	  hearts.	  Cardiovasc	  Res	  2010;683-­‐693.	  120.	   Jack	  A.	  Pharmaceuticals:	  perils	  for	  pill	  pushers.	  Financial	  Times	  2010;Sept	  21	  2010.	  121.	   Watkins	  PB.	  Drug	  safety	  sciences	  and	  the	  bottleneck	  in	  drug	  development.	  Clin	  Pharmacol	  Ther	  2011;89:788-­‐90.	  **	  An	  excellent	  commentary	  on	  contemporary	  issues	  in	  benefit-­‐versus-­‐risk	  drug	  profiling.	  	  	  
